

HEALTHSOUTH CORP
Form 10-Q
October 28, 2014

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2014

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number 001-10315

HealthSouth Corporation
(Exact name of Registrant as specified in its Charter)

Delaware 63-0860407
(State or Other Jurisdiction of (I.R.S. Employer
Incorporation or Organization) Identification No.)

3660 Grandview Parkway, Suite 200 35243
Birmingham, Alabama
(Address of Principal Executive Offices) (Zip Code)

(205) 967-7116
(Registrant's telephone number)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer," and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer Accelerated filer Non-Accelerated filer Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Exchange Act Rule 12b-2).
Yes No

The registrant had 87,752,931 shares of common stock outstanding, net of treasury shares, as of October 21, 2014.

TABLE OF CONTENTS

| | Page |
|---|-----------|
| <u>PART I</u> <u>Financial Information</u> | |
| <u>Item 1.</u> <u>Financial Statements (Unaudited)</u> | <u>1</u> |
| <u>Item 2.</u> <u>Management’s Discussion and Analysis of Financial Condition and Results of Operations</u> | <u>33</u> |
| <u>Item 3.</u> <u>Quantitative and Qualitative Disclosures about Market Risk</u> | <u>52</u> |
| <u>Item 4.</u> <u>Controls and Procedures</u> | <u>52</u> |
| | |
| <u>PART II</u> <u>Other Information</u> | |
| | |
| <u>Item 1.</u> <u>Legal Proceedings</u> | <u>53</u> |
| <u>Item 1A.</u> <u>Risk Factors</u> | <u>53</u> |
| <u>Item 2.</u> <u>Unregistered Sales of Equity Securities and Use of Proceeds</u> | <u>53</u> |
| <u>Item 6.</u> <u>Exhibits</u> | <u>54</u> |

NOTE TO READERS

As used in this report, the terms “HealthSouth,” “we,” “us,” “our,” and the “Company” refer to HealthSouth Corporation and its consolidated subsidiaries, unless otherwise stated or indicated by context. This drafting style is suggested by the Securities and Exchange Commission and is not meant to imply that HealthSouth Corporation, the publicly traded parent company, owns or operates any specific asset, business, or property. The hospitals, operations, and businesses described in this filing are primarily owned and operated by subsidiaries of the parent company. In addition, we use the term “HealthSouth Corporation” to refer to HealthSouth Corporation alone wherever a distinction between HealthSouth Corporation and its subsidiaries is required or aids in the understanding of this filing.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This quarterly report contains historical information, as well as forward-looking statements that involve known and unknown risks and relate to, among other things, future events, changes to Medicare reimbursement and other healthcare laws and regulations from time to time, regulatory investigations, our business strategy, our dividend and stock repurchase strategies, our financial plans, our growth plans, our future financial performance, our projected business results, our ability to create shareholder value, or our projected capital expenditures. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “could,” “should,” “expect,” “plan,” “anticipate,” “intend,” “estimate,” “predict,” “project,” “target,” “potential,” or “continue” or the negative of these terms or other comparable terminology. Such forward-looking statements are necessarily estimates based upon current information and involve a number of risks and uncertainties, many of which are beyond our control. Any forward-looking statement is based on information current as of the date of this report and speaks only as of the date on which such statement is made. Actual events or results may differ materially from the results anticipated in these forward-looking statements as a result of a variety of factors. While it is impossible to identify all such factors, factors that could cause actual events or results to differ materially from those estimated by us include, but are not limited to, the following:

- each of the factors discussed in Item 1A, Risk Factors, of our Annual Report on Form 10-K for the year ended December 31, 2013, as well as uncertainties and factors discussed elsewhere in this Form 10-Q, in our other filings from time to time with the SEC, or in materials incorporated therein by reference;
- changes in the rules and regulations of the healthcare industry at either or both of the federal and state levels, including those contemplated now and in the future as part of national healthcare reform and deficit reduction such as the transformation of the current healthcare system to coordinated care delivery and payment models, the reinstatement of the “75% Rule,” or the introduction of site neutral payments with skilled nursing facilities for certain conditions, and related increases in the costs of complying with such changes;

reductions or delays in, or suspension of, reimbursement for our services by governmental or private payors, including our ability to obtain and retain favorable arrangements with third-party payors;

increased costs of regulatory compliance and compliance monitoring in the healthcare industry, including the costs of investigating and defending asserted claims, whether meritorious or not, and the potential reputational harm associated with those claims;

the ability of each of our hospitals to maintain licensure, certification, and accreditation necessary to operate and receive reimbursement;

our ability to attract and retain nurses, therapists, and other healthcare professionals in a highly competitive environment with often severe staffing shortages and the impact on our labor expenses from potential union activity and staffing recruitment and retention;

- competitive pressures in the healthcare industry and our response to those pressures;

our ability to successfully complete and integrate de novo developments, acquisitions, investments, and joint ventures consistent with our growth strategy, including realization of anticipated revenues, cost savings, and productivity improvements arising from the related operations and avoidance of unforeseen exposure to liabilities;

any adverse outcome of various lawsuits, claims, and legal or regulatory proceedings, including the ongoing investigations initiated by the U.S. Department of Health and Human Services, Office of the Inspector General;

increased costs of defending and insuring against alleged professional liability and other claims and the ability to predict the costs related to such claims;

potential incidents affecting the proper operation, availability, or security of our information systems, including unauthorized access to or theft of patient or other sensitive information;

the price of our common or preferred stock as it affects our willingness and ability to repurchase shares and the financial and accounting effects of any repurchases;

our ability and willingness to continue to declare and pay dividends on our common stock;

our ability to attract and retain key management personnel; and

general conditions in the economy and capital markets, including any instability or uncertainty related to political disputes or impasses over the United States federal budget or similar matters affecting federal spending.

The cautionary statements referred to in this section also should be considered in connection with any subsequent written or oral forward-looking statements that may be issued by us or persons acting on our behalf. We undertake no duty to update these forward-looking statements, even though our situation may change in the future. Furthermore, we cannot guarantee future results, events, levels of activity, performance, or achievements or their effects on the value of our securities.

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements (Unaudited)

HealthSouth Corporation and Subsidiaries

Condensed Consolidated Statements of Operations

(Unaudited)

| | Three Months Ended | | Nine Months Ended | |
|---|--------------------|---------|-------------------|-----------|
| | September 30, | | September 30, | |
| | 2014 | 2013 | 2014 | 2013 |
| | (In Millions) | | | |
| Net operating revenues | \$596.9 | \$564.0 | \$1,792.5 | \$1,701.1 |
| Less: Provision for doubtful accounts | (8.2 |) (8.0 |) (25.0 |) (22.4 |
| Net operating revenues less provision for doubtful accounts | 588.7 | 556.0 | 1,767.5 | 1,678.7 |
| Operating expenses: | | | | |
| Salaries and benefits | 290.0 | 269.5 | 861.4 | 817.7 |
| Other operating expenses | 89.4 | 82.2 | 260.2 | 241.3 |
| Occupancy costs | 10.3 | 11.7 | 31.1 | 35.8 |
| Supplies | 26.6 | 25.5 | 82.0 | 78.3 |
| General and administrative expenses | 27.5 | 28.8 | 88.4 | 88.5 |
| Depreciation and amortization | 27.4 | 24.3 | 80.2 | 69.5 |
| Government, class action, and related settlements | — | (21.3 |) (0.8 |) (23.3 |
| Professional fees—accounting, tax, and legal | 4.0 | 4.2 | 7.6 | 7.8 |
| Total operating expenses | 475.2 | 424.9 | 1,410.1 | 1,315.6 |
| Interest expense and amortization of debt discounts and fees | 27.8 | 25.3 | 83.5 | 73.9 |
| Other income | (0.2 |) (0.6 |) (30.1 |) (3.2 |
| Equity in net income of nonconsolidated affiliates | (1.9 |) (2.0 |) (8.8 |) (8.2 |
| Income from continuing operations before income tax expense (benefit) | 87.8 | 108.4 | 312.8 | 300.6 |
| Provision for income tax expense (benefit) | 22.1 | 35.2 | 91.4 | (17.8 |
| Income from continuing operations | 65.7 | 73.2 | 221.4 | 318.4 |
| (Loss) income from discontinued operations, net of tax | (0.9 |) (0.9 |) 2.8 | (1.2 |
| Net income | 64.8 | 72.3 | 224.2 | 317.2 |
| Less: Net income attributable to noncontrolling interests | (14.7 |) (14.1 |) (44.3 |) (42.5 |
| Net income attributable to HealthSouth | 50.1 | 58.2 | 179.9 | 274.7 |
| Less: Convertible perpetual preferred stock dividends | (1.6 |) (5.7 |) (4.7 |) (17.2 |
| Net income attributable to HealthSouth common shareholders | \$48.5 | \$52.5 | \$175.2 | \$257.5 |

(Continued)

1

HealthSouth Corporation and Subsidiaries
Condensed Consolidated Statements of Operations (Continued)
(Unaudited)

| | Three Months Ended September 30, | | Nine Months Ended September 30, | | |
|---|--------------------------------------|---------|------------------------------------|---------|---|
| | 2014 | 2013 | 2014 | 2013 | |
| | (In Millions, Except Per Share Data) | | | | |
| Weighted average common shares outstanding: | | | | | |
| Basic | 86.5 | 86.2 | 86.8 | 88.7 | |
| Diluted | 100.5 | 100.4 | 100.7 | 102.4 | |
| Earnings per common share: | | | | | |
| Basic earnings per share attributable to HealthSouth common shareholders: | | | | | |
| Continuing operations | \$0.56 | \$0.61 | \$1.96 | \$2.87 | |
| Discontinued operations | (0.01 |) (0.01 |) 0.03 | (0.01 |) |
| Net income | \$0.55 | \$0.60 | \$1.99 | \$2.86 | |
| Diluted earnings per share attributable to HealthSouth common shareholders: | | | | | |
| Continuing operations | \$0.53 | \$0.59 | \$1.82 | \$2.69 | |
| Discontinued operations | (0.01 |) (0.01 |) 0.03 | (0.01 |) |
| Net income | \$0.52 | \$0.58 | \$1.85 | \$2.68 | |
| Cash dividends per common share | \$0.21 | \$0.18 | \$0.57 | \$0.18 | |
| Amounts attributable to HealthSouth common shareholders: | | | | | |
| Income from continuing operations | \$51.0 | \$59.1 | \$177.1 | \$275.9 | |
| (Loss) income from discontinued operations, net of tax | (0.9 |) (0.9 |) 2.8 | (1.2 |) |
| Net income attributable to HealthSouth | \$50.1 | \$58.2 | \$179.9 | \$274.7 | |

The accompanying notes to condensed consolidated financial statements are an integral part of these condensed statements.

HealthSouth Corporation and Subsidiaries
Condensed Consolidated Statements of Comprehensive Income
(Unaudited)

| | Three Months Ended September 30, 2014 | | 2013 | | Nine Months Ended September 30, 2014 | | 2013 | |
|---|---|---|--------|---|--|---|---------|---|
| | (In Millions) | | | | | | | |
| COMPREHENSIVE INCOME | | | | | | | | |
| Net income | \$64.8 | | \$72.3 | | \$224.2 | | \$317.2 | |
| Other comprehensive (loss) income, net of tax: | | | | | | | | |
| Net change in unrealized (loss) gain on available-for-sale securities: | | | | | | | | |
| Unrealized net holding (loss) gain arising during the period | (0.2 |) | — | | 0.5 | | (0.8 |) |
| Reclassifications to net income | — | | 0.1 | | (0.5 |) | (0.9 |) |
| Other comprehensive (loss) income before income taxes | (0.2 |) | 0.1 | | — | | (1.7 |) |
| Provision for income tax benefit related to other comprehensive (loss) income items | 0.1 | | — | | — | | 0.1 | |
| Other comprehensive (loss) income, net of tax | (0.1 |) | 0.1 | | — | | (1.6 |) |
| Comprehensive income | 64.7 | | 72.4 | | 224.2 | | 315.6 | |
| Comprehensive income attributable to noncontrolling interests | (14.7 |) | (14.1 |) | (44.3 |) | (42.5 |) |
| Comprehensive income attributable to HealthSouth | \$50.0 | | \$58.3 | | \$179.9 | | \$273.1 | |

The accompanying notes to condensed consolidated financial statements are an integral part of these condensed statements.

HealthSouth Corporation and Subsidiaries
Condensed Consolidated Balance Sheets
(Unaudited)

| | September 30, 2014 | December 31, 2013 |
|---|-----------------------|----------------------|
| | (In Millions) | |
| Assets | | |
| Current assets: | | |
| Cash and cash equivalents | \$272.3 | \$64.5 |
| Accounts receivable, net of allowance for doubtful accounts of \$24.2 in 2014; \$23.1 in 2013 | 261.6 | 261.8 |
| Deferred income tax assets | 138.9 | 139.0 |
| Other current assets | 110.2 | 115.1 |
| Total current assets | 783.0 | 580.4 |
| Property and equipment, net | 994.6 | 910.5 |
| Goodwill | 491.7 | 456.9 |
| Intangible assets, net | 99.9 | 88.2 |
| Deferred income tax assets | 255.3 | 354.3 |
| Other long-term assets | 169.5 | 144.1 |
| Total assets | \$2,794.0 | \$2,534.4 |
| Liabilities and Shareholders' Equity | | |
| Current liabilities: | | |
| Current portion of long-term debt | \$208.5 | \$12.3 |
| Accounts payable | 54.8 | 61.9 |
| Accrued expenses and other current liabilities | 251.4 | 237.4 |
| Total current liabilities | 514.7 | 311.6 |
| Long-term debt, net of current portion | 1,441.4 | 1,505.2 |
| Other long-term liabilities | 139.7 | 142.2 |
| | 2,095.8 | 1,959.0 |
| Commitments and contingencies | | |
| Convertible perpetual preferred stock | 93.2 | 93.2 |
| Redeemable noncontrolling interests | 12.2 | 13.5 |
| Shareholders' equity: | | |
| HealthSouth shareholders' equity | | |
| Common stock, \$.01 par value; 200,000,000 shares authorized; issued: 104,011,178 in 2014; 102,648,302 in 2013 | 1.0 | 1.0 |
| Capital in excess of par value | 2,828.0 | 2,849.4 |
| Accumulated deficit | (1,921.2 |) (2,101.1 |
| Accumulated other comprehensive loss | (0.1 |) (0.1 |
| Treasury stock, at cost (16,255,544 shares in 2014 and 14,654,436 shares in 2013) | (458.1 |) (404.6 |
| Total HealthSouth shareholders' equity | 449.6 | 344.6 |
| Noncontrolling interests | 143.2 | 124.1 |
| Total shareholders' equity | 592.8 | 468.7 |
| Total liabilities and shareholders' equity | \$2,794.0 | \$2,534.4 |

The accompanying notes to condensed consolidated financial statements are an integral part of these condensed statements.

Edgar Filing: HEALTHSOUTH CORP - Form 10-Q

HealthSouth Corporation and Subsidiaries
Condensed Consolidated Statements of Shareholders' Equity
(Unaudited)

| Nine Months Ended September 30, 2014 (In Millions) | | | | | | | | |
|---|---|-----------------|--------------------------------------|------------------------|---|-------------------|-----------------------------|---------|
| HealthSouth Common Shareholders | | | | | | | | |
| | Number of Common Shares Outstanding | Common Stock | Capital in Excess of Par Value | Accumulated Deficit | Accumulated Other Comprehensive Loss | Treasury Stock | Noncontrolling Interests | Total |
| Balance at beginning of period | 88.0 | \$ 1.0 | \$2,849.4 | \$ (2,101.1) | \$ (0.1) | \$(404.6) | \$ 124.1 | \$468.7 |
| Net income | — | — | — | 179.9 | — | — | 38.9 | 218.8 |
| Receipt of treasury stock | (0.3) | — | — | — | — | (9.7) | — | (9.7) |
| Dividends declared on common stock | — | — | (50.6) | — | — | — | — | (50.6) |
| Dividends declared on convertible perpetual preferred stock | — | — | (4.7) | — | — | — | — | (4.7) |
| Stock-based compensation | — | — | 19.3 | — | — | — | — | 19.3 |
| Stock options exercised | 0.3 | — | 7.4 | — | — | — | — | 7.4 |
| Stock warrants exercised | 0.2 | — | 6.3 | — | — | — | — | 6.3 |
| Distributions declared | — | — | — | — | — | — | (33.7) | (33.7) |
| Repurchases of common stock in open market | (1.3) | — | — | — | — | (43.1) | — | (43.1) |
| Consolidation of Fairlawn Rehabilitation Hospital | — | — | — | — | — | — | 14.0 | 14.0 |
| Other | 0.9 | — | 0.9 | — | — | (0.7) | (0.1) | 0.1 |
| Balance at end of period | 87.8 | \$ 1.0 | \$2,828.0 | \$ (1,921.2) | \$ (0.1) | \$(458.1) | \$ 143.2 | \$592.8 |

| Nine Months Ended September 30, 2013 (In Millions) | | | | | | | | |
|---|---|-----------------|--------------------------------------|------------------------|---|-------------------|-----------------------------|---------|
| HealthSouth Common Shareholders | | | | | | | | |
| | Number of Common Shares Outstanding | Common Stock | Capital in Excess of Par Value | Accumulated Deficit | Accumulated Other Comprehensive Income (Loss) | Treasury Stock | Noncontrolling Interests | Total |
| Balance at beginning of period | 95.7 | \$ 1.0 | \$2,876.6 | \$ (2,424.7) | \$ 1.4 | \$(163.3) | \$ 112.5 | \$403.5 |
| Net income | — | — | — | 274.7 | — | — | 38.4 | 313.1 |
| Receipt of treasury stock | (0.3) | — | — | — | — | (5.8) | — | (5.8) |
| Dividends declared on common stock | — | — | (15.9) | — | — | — | — | (15.9) |
| Dividends declared on convertible perpetual preferred stock | — | — | (17.2) | — | — | — | — | (17.2) |

Edgar Filing: HEALTHSOUTH CORP - Form 10-Q

| | | | | | | | |
|---|--------|--------|-----------|---------------|-----------|-------------|----------|
| Stock-based compensation— | — | 19.0 | — | — | — | — | 19.0 |
| Stock options exercised | 0.3 | — | 7.5 | — | — | — | 7.5 |
| Distributions declared | — | — | — | — | — | (30.1) | (30.1) |
| Repurchases of common stock through tender offer | (9.1) | — | — | — | — | (234.1) | (234.1) |
| Other | 0.8 | — | 4.5 | — | (1.6) | (1.0) | 0.1 |
| Balance at end of period | 87.4 | \$ 1.0 | \$2,874.5 | \$ (2,150.0) | \$ (0.2) | \$ (404.2) | \$ 120.9 |
| | | | | | | | \$442.0 |

The accompanying notes to condensed consolidated financial statements are an integral part of these condensed statements.

5

HealthSouth Corporation and Subsidiaries
Condensed Consolidated Statements of Cash Flows
(Unaudited)

| | Nine Months Ended September 30, | |
|---|---------------------------------|---------|
| | 2014 | 2013 |
| | (In Millions) | |
| Cash flows from operating activities: | | |
| Net income | \$224.2 | \$317.2 |
| (Income) loss from discontinued operations | (2.8 |) 1.2 |
| Adjustments to reconcile net income to net cash provided by operating activities— | | |
| Provision for doubtful accounts | 25.0 | 22.4 |
| Provision for government, class action, and related settlements | (0.8 |) (23.3 |
| Depreciation and amortization | 80.2 | 69.5 |
| Equity in net income of nonconsolidated affiliates | (8.8 |) (8.2 |
| Distributions from nonconsolidated affiliates | 9.4 | 9.6 |
| Stock-based compensation | 19.3 | 19.0 |
| Deferred tax expense (benefit) | 81.6 | (20.8 |
| Gain on consolidation of Fairlawn Rehabilitation Hospital | (27.2 |) — |
| Other | 13.0 | 6.0 |
| (Increase) decrease in assets— | | |
| Accounts receivable | (48.7 |) (26.5 |
| Other assets | 8.9 | (4.5 |
| Increase (decrease) in liabilities— | | |
| Accounts payable | 3.7 | 9.9 |
| Other liabilities | (7.6 |) (0.7 |
| Premium received on bond issuance | 6.3 | — |
| Net cash used in operating activities of discontinued operations | (1.0 |) (1.4 |
| Total adjustments | 153.3 | 51.0 |
| Net cash provided by operating activities | 374.7 | 369.4 |

(Continued)

6

HealthSouth Corporation and Subsidiaries
Condensed Consolidated Statements of Cash Flows (Continued)
(Unaudited)

| | Nine Months Ended September 30, | |
|---|---------------------------------|----------|
| | 2014 | 2013 |
| | (In Millions) | |
| Cash flows from investing activities: | | |
| Purchases of property and equipment | (133.9 |) (166.8 |
| Capitalized software costs | (12.6 |) (15.6 |
| Acquisition of business, net of cash acquired | (15.9 |) (28.9 |
| Proceeds from sale of restricted investments | 0.3 | 16.9 |
| Proceeds from sale of Digital Hospital | — | 10.8 |
| Purchase of restricted investments | (2.5 |) (8.1 |
| Other | 2.3 | (5.5 |
| Net cash used in investing activities | (162.3 |) (197.2 |
| Cash flows from financing activities: | | |
| Proceeds from bond issuance | 175.0 | — |
| Principal borrowings on notes | — | 15.2 |
| Borrowings on revolving credit facility | 65.0 | 147.0 |
| Payments on revolving credit facility | (110.0 |) (112.0 |
| Repurchases of common stock, including fees and expenses | (43.1 |) (234.1 |
| Dividends paid on common stock | (47.4 |) — |
| Dividends paid on convertible perpetual preferred stock | (4.7 |) (17.2 |
| Distributions paid to noncontrolling interests of consolidated affiliates | (39.6 |) (34.1 |
| Other | 0.2 | (4.8 |
| Net cash used in financing activities | (4.6 |) (240.0 |
| Increase (decrease) in cash and cash equivalents | 207.8 | (67.8 |
| Cash and cash equivalents at beginning of period | 64.5 | 132.8 |
| Cash and cash equivalents at end of period | \$272.3 | \$65.0 |

The accompanying notes to condensed consolidated financial statements are an integral part of these condensed statements.

HealthSouth Corporation and Subsidiaries
Notes to Condensed Consolidated Financial Statements

1. Basis of Presentation

HealthSouth Corporation, incorporated in Delaware in 1984, including its subsidiaries, is the largest owner and operator of inpatient rehabilitation hospitals in the United States in terms of patients treated and discharged, revenues, and number of hospitals. We operate inpatient rehabilitation hospitals and provide specialized rehabilitative treatment on both an inpatient and outpatient basis.

The accompanying unaudited condensed consolidated financial statements of HealthSouth Corporation and Subsidiaries should be read in conjunction with the consolidated financial statements and accompanying notes filed with the United States Securities and Exchange Commission in HealthSouth's Annual Report on Form 10-K filed on February 20, 2014 (the "2013 Form 10-K"). The unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the SEC applicable to interim financial information. Certain information and note disclosures included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America have been omitted in these interim statements, as allowed by such SEC rules and regulations. The condensed consolidated balance sheet as of December 31, 2013 has been derived from audited financial statements, but it does not include all disclosures required by GAAP. However, we believe the disclosures are adequate to make the information presented not misleading.

The unaudited results of operations for the interim periods shown in these financial statements are not necessarily indicative of operating results for the entire year. In our opinion, the accompanying condensed consolidated financial statements recognize all adjustments of a normal recurring nature considered necessary to fairly state the financial position, results of operations, and cash flows for each interim period presented.

See also Note 2, Business Combinations.

Net Operating Revenues—

During the three and nine months ended September 30, 2014 and 2013, we derived consolidated Net operating revenues from the following payor sources:

| | Three Months Ended September | | Nine Months Ended September | | |
|---|------------------------------|---------|-----------------------------|---------|---|
| | 30, 2014 | 2013 | 30, 2014 | 2013 | |
| Medicare | 73.5 | % 74.1 | % 74.1 | % 74.5 | % |
| Medicaid | 2.2 | % 1.5 | % 1.8 | % 1.2 | % |
| Workers' compensation | 1.1 | % 1.3 | % 1.2 | % 1.3 | % |
| Managed care and other discount plans, including Medicare Advantage | 18.8 | % 18.7 | % 18.6 | % 18.5 | % |
| Other third-party payors | 1.8 | % 1.7 | % 1.7 | % 1.7 | % |
| Patients | 1.1 | % 1.1 | % 1.0 | % 1.1 | % |
| Other income | 1.5 | % 1.6 | % 1.6 | % 1.7 | % |
| Total | 100.0 | % 100.0 | % 100.0 | % 100.0 | % |

See Note 1, Summary of Significant Accounting Policies, to the consolidated financial statements accompanying the 2013 Form 10-K for our policies related to Net operating revenues, Accounts receivable, and our Allowance for doubtful accounts.

HealthSouth Corporation and Subsidiaries
Notes to Condensed Consolidated Financial Statements

2. Business Combinations

In June 2014, we acquired an additional 30% equity interest from UMass Memorial Health Care, our joint venture partner in Fairlawn Rehabilitation Hospital (“Fairlawn”) in Worcester, Massachusetts. This transaction increased our ownership interest from 50% to 80% and resulted in a change in accounting for this hospital from the equity method of accounting to a consolidated entity. As a result of our consolidation of this hospital and the remeasurement of our previously held equity interest at fair value, Goodwill increased by \$34.8 million, and we recorded a \$27.2 million gain as part of Other income during the nine months ended September 30, 2014. The transaction was funded using cash on hand. See also Note 9, Income Taxes.

We entered into this transaction to increase our ownership in this profitable hospital and continue to grow our core business by consolidating its operations. None of the goodwill resulting from this transaction is deductible for federal income tax purposes. The goodwill reflects our expectations of our ability to continue to serve the consolidated hospital’s historical patient base as well as favorable growth opportunities based on positive demographic trends in this market.

We accounted for this transaction under the acquisition method of accounting and reported the results of operations of Fairlawn from the date of acquisition. Assets acquired and liabilities assumed were recorded at their estimated fair values as of the acquisition date. The fair values of identifiable intangible assets were based on valuations using the cost and income approaches. The cost approach is based on amounts that would be required to replace the asset (i.e., replacement cost). The income approach is based on management’s estimates of future operating results and cash flows discounted using a weighted-average cost of capital that reflects market participant assumptions. The excess of the fair value of the consideration conveyed over the fair value of the net assets acquired was recorded as goodwill.

The fair value of the assets acquired and liabilities assumed at the acquisition date were as follows (in millions):

| | | |
|---|---------|---|
| Total current assets | \$ 12.1 | |
| Property and equipment, net | 30.4 | |
| Identifiable intangible assets: | | |
| Noncompete agreement (useful life of 3 years) | 0.4 | |
| Tradename (useful life of 20 years) | 2.5 | |
| Certificate of need (useful life of 20 years) | 9.7 | |
| License (useful life of 20 years) | 2.0 | |
| Goodwill | 34.8 | |
| Total assets acquired | 91.9 | |
| Total current liabilities assumed | (7.8 |) |
| Total long-term liabilities assumed | (14.1 |) |
| Net assets acquired | \$ 70.0 | |

HealthSouth Corporation and Subsidiaries
Notes to Condensed Consolidated Financial Statements

Our reported Net operating revenues and Net income for the three and nine months ended September 30, 2014 include operating results for Fairlawn from June 1, 2014 through September 30, 2014. The following table summarizes the results of operations of the above mentioned entity from the date of acquisition included in our consolidated results of operations and the results of operations of the combined entity had the date of the acquisition been January 1, 2013 (in millions):

| | Net Operating Revenues | Net Income Attributable to HealthSouth |
|--|------------------------|--|
| Acquired entity only: Actual from acquisition date to September 30, 2014 | \$ 15.4 | \$ 2.6 |
| Combined entity: Supplemental pro forma from 07/01/2014-09/30/2014* | 596.9 | 50.1 |
| Combined entity: Supplemental pro forma from 07/01/2013-09/30/2013 | 574.8 | 59.3 |
| Combined entity: Supplemental pro forma from 01/01/2014-09/30/2014 | 1,811.3 | 181.6 |
| Combined entity: Supplemental pro forma from 01/01/2013-09/30/2013 | 1,734.4 | 278.0 |

*Pro forma amounts equal reported operating results due to the acquisition of Fairlawn effective June 1, 2014.

Information regarding the net cash paid for all acquisitions during each period presented is as follows (in millions):

| | Three Months Ended | | Nine Months Ended | |
|--|--------------------|------|--------------------|---------|
| | September 30, 2014 | 2013 | September 30, 2014 | 2013 |
| Fair value of assets acquired, net of \$5.1 million of cash acquired in 2014 | \$— | \$— | \$52.0 | \$ 15.6 |
| Goodwill | — | — | 34.8 | 13.7 |
| Fair value of liabilities assumed | — | — | (21.9 |) (0.4 |
| Fair value of noncontrolling interest owned by joint venture partner | — | — | (14.0 |) — |
| Fair value of equity interest prior to acquisition | — | — | (35.0 |) — |
| Net cash paid for acquisitions | \$— | \$— | \$ 15.9 | \$28.9 |

See Note 2, Business Combinations, to the 2013 Form 10-K for information regarding the acquisition completed in 2013.

3. Investments in and Advances to Nonconsolidated Affiliates

As of September 30, 2014 and December 31, 2013, we had \$10.8 million and \$20.3 million, respectively, of investments in and advances to nonconsolidated affiliates included in Other long-term assets in our condensed consolidated balance sheets. Investments in and advances to nonconsolidated affiliates represent our investments in nine partially owned subsidiaries, of which eight are general or limited partnerships, limited liability companies, or joint ventures in which HealthSouth or one of its subsidiaries is a general or limited partner, managing member, member, or venturer, as applicable. We do not control these affiliates but have the ability to exercise significant influence over the operating and financial policies of certain of these affiliates. Our ownership percentages in these affiliates range from approximately 1% to 51%. We account for these investments using the cost and equity methods of accounting.

HealthSouth Corporation and Subsidiaries
Notes to Condensed Consolidated Financial Statements

The following summarizes the combined results of operations of our equity method affiliates (on a 100% basis, in millions):

| | Three Months Ended | | Nine Months Ended | |
|---|--------------------|---------|-------------------|---------|
| | September 30, | | September 30, | |
| | 2014 | 2013 | 2014 | 2013 |
| Net operating revenues | \$7.8 | \$16.2 | \$44.1 | \$55.4 |
| Operating expenses | (3.3 |) (10.3 |) (22.7 |) (32.5 |
| Income from continuing operations, net of tax | 4.2 | 4.4 | 28.2 | 18.4 |
| Net income | 4.2 | 4.4 | 28.2 | 18.4 |

See also Note 2, Business Combinations.

4. Long-term Debt

Our long-term debt outstanding consists of the following (in millions):

| | September 30, 2014 | December 31, 2013 |
|---|--------------------|-------------------|
| Credit Agreement— | | |
| Advances under revolving credit facility | \$— | \$45.0 |
| Term loan facility | — | — |
| Bonds payable— | | |
| 7.25% Senior Notes due 2018 | 272.3 | 272.4 |
| 8.125% Senior Notes due 2020 | 286.9 | 286.6 |
| 7.75% Senior Notes due 2022 | 252.4 | 252.5 |
| 5.75% Senior Notes due 2024 | 456.3 | 275.0 |
| 2.0% Convertible Senior Subordinated Notes due 2043 | 255.8 | 249.5 |
| Other notes payable | 41.9 | 47.6 |
| Capital lease obligations | 84.3 | 88.9 |
| | 1,649.9 | 1,517.5 |
| Less: Current portion | (208.5 |) (12.3 |
| Long-term debt, net of current portion | \$1,441.4 | \$1,505.2 |

HealthSouth Corporation and Subsidiaries
Notes to Condensed Consolidated Financial Statements

The following chart shows scheduled principal payments due on long-term debt for the next five years and thereafter (in millions):

| | Face Amount | Net Amount |
|--------------------------------------|-------------|------------|
| October 1 through December 31, 2014* | \$273.3 | \$274.2 |
| 2015 | 9.0 | 9.0 |
| 2016 | 9.0 | 9.0 |
| 2017 | 8.1 | 8.1 |
| 2018 | 8.6 | 8.6 |
| 2019 | 11.5 | 11.5 |
| Thereafter | 1,389.1 | 1,329.5 |
| Total | \$1,708.6 | \$1,649.9 |

*See discussion below regarding the notice and redemption of our 7.25% Senior Notes due 2018.

On September 18, 2014, we issued an additional \$175 million of our existing 5.75% Senior Notes due 2024 at a price of 103.625% of the principal amount, which resulted in approximately \$182 million in net proceeds from the public offering. The additional notes will be governed by the previously executed agreements for our 5.75% Senior Notes due 2024.

On September 22, 2014, we amended our existing credit agreement to, among other things:

- add a new \$150 million term loan facility in addition to our existing \$600 million revolving credit facility;
- permit additional restricted payments so long as the senior secured leverage ratio remains less than or equal to 1.75x (previously 1.50x);
- increase the amount of permitted capital expenditures in a given year from \$250 million to \$300 million; and
- set the maturity date for both the revolving credit and term loan facilities to September 20, 2019, which represents a one-year extension for our existing revolving credit facility.

We may borrow amounts under the term loan facility on or before March 31, 2015. Amounts drawn under the term loan facility are subject to the same applicable interest rate schedule as amounts drawn under our existing revolving credit facility, which rate is currently LIBOR plus 1.75 percent. Amounts drawn under the term loan facility are payable in equal consecutive quarterly installments, commencing on March 31, 2015, of 1.25% of the aggregate principal amount of the term loan outstanding as of March 31, 2015. We have the right at any time to prepay, in whole or in part, any borrowing under the term loan facility.

On August 29, 2014, we gave notice of, and made an irrevocable commitment for, the redemption of all the outstanding principal amount of our 7.25% Senior Notes due 2018. On October 1, 2014, we used the net proceeds from the additional offering of our 5.75% Senior Notes due 2024, a \$75 million draw under our term loan facility, and cash on hand to execute the redemption. Pursuant to the terms of the 7.25% Senior Notes due 2018, this redemption was made at a price of 103.625%, which resulted in a total cash outlay of approximately \$281 million to retire the approximately \$271 million in principal. Additionally, on October 24, 2014, we gave notice of the redemption of approximately \$25 million of the outstanding principal amount of our existing 7.75% Senior Notes due 2022. Pursuant to the terms of the 7.75% Senior Notes due 2022, this optional redemption will represent 10% of the outstanding principal amount of the notes at a price of 103%, which will result in a total cash outlay of approximately \$26 million when the transaction closes in December 2014. As a result of these redemptions, we expect to record an approximate \$13 million loss on early extinguishment of debt in the fourth quarter of 2014.

For additional information regarding our indebtedness, see Note 8, Long-term Debt, to the consolidated financial statements accompanying the 2013 Form 10-K.

HealthSouth Corporation and Subsidiaries
Notes to Condensed Consolidated Financial Statements

5. Redeemable Noncontrolling Interests

The following is a summary of the activity related to our Redeemable noncontrolling interests during the nine months ended September 30, 2014 and 2013 (in millions):

| | Nine Months Ended September 30, | |
|---|---------------------------------|--------|
| | 2014 | 2013 |
| Balance at beginning of period | \$13.5 | \$7.2 |
| Net income attributable to noncontrolling interests | 5.4 | 4.1 |
| Distributions declared | (6.7 |) (3.6 |
| Contribution to joint venture | — | 6.2 |
| Balance at end of period | \$12.2 | \$13.9 |

The following table reconciles the net income attributable to nonredeemable Noncontrolling interests, as recorded in the shareholders' equity section of the condensed consolidated balance sheets, and the net income attributable to Redeemable noncontrolling interests, as recorded in the mezzanine section of the condensed consolidated balance sheets, to the Net income attributable to noncontrolling interests presented in the condensed consolidated statements of operations for the three and nine months ended September 30, 2014 and 2013 (in millions):

| | Three Months Ended | | Nine Months Ended | |
|---|--------------------|--------|-------------------|--------|
| | September 30, | | September 30, | |
| | 2014 | 2013 | 2014 | 2013 |
| Net income attributable to nonredeemable noncontrolling interests | \$12.9 | \$12.6 | \$38.9 | \$38.4 |
| Net income attributable to redeemable noncontrolling interests | 1.8 | 1.5 | 5.4 | 4.1 |
| Net income attributable to noncontrolling interests | \$14.7 | \$14.1 | \$44.3 | \$42.5 |

HealthSouth Corporation and Subsidiaries
Notes to Condensed Consolidated Financial Statements

6. Fair Value Measurements

Our financial assets and liabilities that are measured at fair value on a recurring basis are as follows (in millions):

| As of September 30, 2014 | Fair Value | Fair Value Measurements at Reporting Date Using | | | Valuation Technique ⁽¹⁾ |
|---|------------|--|---|---|------------------------------------|
| | | Quoted Prices in Active Markets for Identical Assets (Level 1) | Significant Other Observable Inputs (Level 2) | Significant Unobservable Inputs (Level 3) | |
| Other current assets: | | | | | |
| Current portion of restricted marketable securities | \$4.3 | \$— | \$4.3 | \$— | M |
| Other long-term assets: | | | | | |
| Restricted marketable securities | 45.9 | — | 45.9 | — | M |
| As of December 31, 2013 | | | | | |
| Other current assets: | | | | | |
| Current portion of restricted marketable securities | \$4.7 | \$— | \$4.7 | \$— | M |
| Other long-term assets: | | | | | |
| Restricted marketable securities | 42.9 | — | 42.9 | — | M |

⁽¹⁾ The three valuation techniques are: market approach (M), cost approach (C), and income approach (I).

In addition to assets and liabilities recorded at fair value on a recurring basis, we are also required to record assets and liabilities at fair value on a nonrecurring basis. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges or similar adjustments made to the carrying value of the applicable assets.

During the three months ended September 30, 2014, we did not record any gains or losses related to our nonfinancial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a nonrecurring basis as part of our continuing operations. As a result of our consolidation of Fairlawn and the remeasurement of our previously held equity interest at fair value, we recorded a \$27.2 million gain as part of Other income during the nine months ended September 30, 2014. We determined the fair value of our previously held equity interest using the income approach. The income approach included the use of the hospital's projected operating results and cash flows discounted using a rate that reflects market participant assumptions for the hospital. The projected operating results used management's best estimates of economic and market conditions over the forecasted period including assumptions for pricing and volume, operating expenses, and capital expenditures. See Note 2, Business Combinations. During the three and nine months ended September 30, 2013, we did not record any material gains or losses related to our nonfinancial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a nonrecurring basis as part of our continuing operations.

During the three and nine months ended September 30, 2013, we recorded an impairment charge of \$1.1 million as part of our results of discontinued operations. This charge related to a hospital that was closed in 2011. We determined the fair value of the impaired long-lived assets at the hospital based on an offer from a potential buyer.

HealthSouth Corporation and Subsidiaries
Notes to Condensed Consolidated Financial Statements

As discussed in Note 1, Summary of Significant Accounting Policies, “Fair Value Measurements,” to the consolidated financial statements accompanying the 2013 Form 10-K, the carrying value equals fair value for our financial instruments that are not included in the table below and are classified as current in our condensed consolidated balance sheets. The carrying amounts and estimated fair values for all of our other financial instruments are presented in the following table (in millions):

| | As of September 30, 2014 | | As of December 31, 2013 | |
|--|--------------------------|----------------------|-------------------------|----------------------|
| | Carrying Amount | Estimated Fair Value | Carrying Amount | Estimated Fair Value |
| Long-term debt: | | | | |
| Advances under revolving credit facility | \$— | \$— | \$45.0 | \$45.0 |
| 7.25% Senior Notes due 2018 | 272.3 | 281.3 | 272.4 | 291.4 |
| 8.125% Senior Notes due 2020 | 286.9 | 306.0 | 286.6 | 319.4 |
| 7.75% Senior Notes due 2022 | 252.4 | 269.0 | 252.5 | 275.0 |
| 5.75% Senior Notes due 2024 | 456.3 | 456.2 | 275.0 | 273.6 |
| 2.00% Convertible Senior Subordinated Notes due 2043 | 255.8 | 349.2 | 249.5 | 339.7 |
| Other notes payable | 41.9 | 41.9 | 47.6 | 47.6 |
| Financial commitments: | | | | |
| Letters of credit | — | 31.8 | — | 36.5 |

Fair values for our long-term debt and financial commitments are determined using inputs, including quoted prices in nonactive markets, that are observable either directly or indirectly, or Level 2 inputs within the fair value hierarchy. See Note 1, Summary of Significant Accounting Policies, “Fair Value Measurements,” to the consolidated financial statements accompanying the 2013 Form 10-K.

See also Note 5, Redeemable Noncontrolling Interests, and Note 8, Assets and Liabilities in and Results of Discontinued Operations.

7. Share-Based Payments

In February 2014, we issued 0.6 million of restricted stock awards to members of our management team and our board of directors. Approximately 0.2 million of these awards contain only a service condition, while the remainder contain both a service and a performance or market condition. For the awards that include a performance or market condition, the number of shares that will ultimately be granted to employees may vary based on the Company’s performance during the applicable two-year performance measurement period. Additionally, in February 2014, we granted 0.1 million stock options to members of our management team. The fair value of these awards and options was determined using the policies described in Note 1, Summary of Significant Accounting Policies, and Note 13, Share-Based Payments, to the consolidated financial statements accompanying the 2013 Form 10-K.

8. Assets and Liabilities in and Results of Discontinued Operations

In connection with the 2007 sale of our surgery centers division (now known as Surgical Care Affiliates, or “SCA”) to ASC Acquisition LLC, an affiliate of TPG Partners V, L.P. (“TPG”), a private investment partnership, we received an option, subject to terms and conditions set forth below, to purchase up to a 5% equity interest in SCA. The price of the option is equal to the original issuance price of the units subscribed for by TPG and certain other co-investors in connection with the acquisition plus a 15% premium, compounded annually. The option has a term of ten years and is exercisable upon certain liquidity events, including a public offering of SCA’s shares of common stock that results in 30% or more of SCA’s common stock being listed or traded on a national securities exchange. On November 4, 2013, SCA announced the closing of its initial public offering, which was not a qualifying liquidity event.

During the second quarter of 2014, we entered into an amendment to the option agreement that requires us to settle the option net of our exercise price. The addition of this new feature resulted in the option becoming a derivative that must be recorded as an asset or liability on our condensed consolidated balance sheet and marked to market each period. As of

HealthSouth Corporation and Subsidiaries
Notes to Condensed Consolidated Financial Statements

September 30, 2014, the fair value of this option was \$5.1 million and is included in Other long-term assets in our condensed consolidated balance sheet. Income from discontinued operations, net of tax for the three and nine months ended September 30, 2014 included a \$1.6 million loss and \$5.1 million net gain, respectively, resulting from the initial recording of this option as a derivative and its fair value adjustments during the 2014 periods presented. The fair value of the option and related adjustments were determined using a lattice model. Inputs into the model included the historical price volatility of SCA's common stock, the risk free interest rate, and probability factors for the timing of when the option will be exercisable, or Level 3 inputs. For additional information regarding discontinued operations, see Note 15, Assets and Liabilities in and Results of Discontinued Operations, to the consolidated financial statements accompanying the 2013 Form 10-K.

9. Income Taxes

Our Provision for income tax expense of \$22.1 million and \$91.4 million for the three and nine months ended September 30, 2014, respectively, primarily resulted from the application of our estimated effective blended federal and state income tax rates, which were reduced as a result of the nontaxable gain discussed in Note 2, Business Combinations, related to our acquisition of an additional 30% equity interest in Fairlawn and our election to claim certain tax credits. As a result of the Fairlawn transaction, we released the deferred tax liability associated with the outside tax basis of our investment in Fairlawn because we now possess sufficient ownership to allow for the historical outside tax basis difference to be resolved through a tax-free transaction in the future.

In April 2013, we entered into closing agreements with the Internal Revenue Service that settled federal income tax matters related to the previous restatement of our 2000 and 2001 financial statements, as well as certain other tax matters, through December 31, 2008. As a result of these closing agreements, we increased our deferred tax assets, primarily our federal net operating loss carryforward ("NOL"), and recorded a net federal income tax benefit of approximately \$115 million in the second quarter of 2013. This federal income tax benefit primarily resulted from an approximate \$283 million increase to our federal NOL on a gross basis.

Our Provision for income tax expense of \$35.2 million for the three months ended September 30, 2013 primarily resulted from the application of our estimated effective blended federal and state income tax rate offset by a decrease in our valuation allowance due to changes in certain state tax laws and provision to return adjustments made as a result of the filing of our federal income tax return for 2012. Our Provision for income tax benefit of \$17.8 million for the nine months ended September 30, 2013 primarily resulted from the IRS settlement discussed above. It also included an approximate \$4 million decrease in our valuation allowance related primarily to our capital loss carryforwards and changes in certain state tax laws. During the second quarter of 2013, we determined a valuation allowance related to our capital loss carryforwards was no longer required as sufficient positive evidence existed to substantiate their utilization. This evidence included our partial utilization of these assets as a result of realizing capital gains in the current year and the identification of sufficient taxable capital gain income within the available capital loss carryforward period.

We have significant federal and state NOLs that expire in various amounts at varying times through 2031. Our utilization of NOLs could be subject to limitations under Internal Revenue Code Section 382 ("Section 382") and may be limited in the event certain cumulative changes in ownership interests of significant stockholders over a three-year period exceed 50%. Section 382 imposes an annual limitation on the use of certain carryforward losses to an amount that approximates the value of a company at the time of an ownership change multiplied by the long-term tax exempt rate. At this time, we do not believe these limitations will restrict our ability to use any NOLs before they expire. However, no such assurances can be provided.

The \$394.2 million of net deferred tax assets included in the accompanying condensed consolidated balance sheet as of September 30, 2014 reflects management's assessment it is more likely than not we will be able to generate sufficient future taxable income to utilize those deferred tax assets based on our current estimates and assumptions. As of September 30, 2014, we maintained a valuation allowance of \$30.3 million due to uncertainties regarding our ability to utilize a portion of our state NOLs before they expire. The amount of the valuation allowance has been determined for each tax jurisdiction based on the weight of all available evidence including management's estimates of taxable income for each jurisdiction in which we operate over the periods in which the related deferred tax assets will

be recoverable. It is possible we may be required to increase or

16

HealthSouth Corporation and Subsidiaries
Notes to Condensed Consolidated Financial Statements

decrease our valuation allowance at some future time if our forecast of future earnings varies from actual results on a consolidated basis or in the applicable state tax jurisdictions, or if the timing of future tax deductions differs from our expectations.

Our reported federal NOL of \$240.7 million (approximately \$688 million on a gross basis) as of September 30, 2014 excludes \$11.3 million related to operating loss carryforwards resulting from excess tax benefits related to share-based awards, the tax benefits of which, when recognized, will be accounted for as a credit to Capital in excess of par value when they reduce taxes payable.

Total remaining gross unrecognized tax benefits were \$0.4 million and \$1.1 million as of September 30, 2014 and December 31, 2013, respectively, none of which would affect our effective tax rate if recognized. A reconciliation of the beginning and ending liability for unrecognized tax benefits is as follows (in millions):

| | Gross Unrecognized Income Tax Benefits | Accrued Interest and Penalties |
|---|---|-----------------------------------|
| Balance at December 31, 2013 | \$1.1 | \$0.3 |
| Gross amount of increases in unrecognized tax benefits related to prior periods | — | 0.1 |
| Gross amount of decreases in unrecognized tax benefits related to prior periods | (0.7 |) (0.3 |
| Balance at September 30, 2014 | \$0.4 | \$0.1 |

Our continuing practice is to recognize interest and penalties related to income tax matters in income tax expense. Interest recorded as part of our income tax provision during the three and nine months ended September 30, 2014 and 2013 was not material. Accrued interest income related to income taxes as of September 30, 2014 and December 31, 2013 was not material.

HealthSouth and its subsidiaries' federal and state income tax returns are periodically examined by various regulatory taxing authorities. In connection with such examinations, we have settled federal income tax examinations with the IRS for all tax years through 2010. We are currently under audit by two states for tax years ranging from 2007 through 2011.

For the tax years that remain open under the applicable statutes of limitation, amounts related to unrecognized tax benefits have been considered by management in its estimate of our potential net recovery of prior years' income taxes. We do not expect a material change in our unrecognized tax benefits within the next 12 months due to the closing of the applicable statutes of limitation.

HealthSouth Corporation and Subsidiaries
Notes to Condensed Consolidated Financial Statements

10. Earnings per Common Share

The following table sets forth the computation of basic and diluted earnings per common share (in millions, except per share amounts):

| | Three Months Ended September 30, | | Nine Months Ended September 30, | |
|---|-------------------------------------|---------|------------------------------------|---------|
| | 2014 | 2013 | 2014 | 2013 |
| Basic: | | | | |
| Numerator: | | | | |
| Income from continuing operations | \$65.7 | \$73.2 | \$221.4 | \$318.4 |
| Less: Net income attributable to noncontrolling interests included in continuing operations | (14.7) | (14.1) | (44.3) | (42.5) |
| Less: Income allocated to participating securities | (0.5) | (0.6) | (2.1) | (4.1) |
| Less: Convertible perpetual preferred stock dividends | (1.6) | (5.7) | (4.7) | (17.2) |
| Income from continuing operations attributable to HealthSouth common shareholders | 48.9 | 52.8 | 170.3 | 254.6 |
| (Loss) income from discontinued operations, net of tax, attributable to HealthSouth common shareholders | (0.9) | (0.9) | 2.8 | (1.2) |
| Net income attributable to HealthSouth common shareholders | \$48.0 | \$51.9 | \$173.1 | \$253.4 |
| Denominator: | | | | |
| Basic weighted average common shares outstanding | 86.5 | 86.2 | 86.8 | 88.7 |
| Basic earnings per share attributable to HealthSouth common shareholders: | | | | |
| Continuing operations | \$0.56 | \$0.61 | \$1.96 | \$2.87 |
| Discontinued operations | (0.01) | (0.01) | 0.03 | (0.01) |
| Net income | \$0.55 | \$0.60 | \$1.99 | \$2.86 |
| Diluted: | | | | |
| Numerator: | | | | |
| Income from continuing operations | \$65.7 | \$73.2 | \$221.4 | \$318.4 |
| Less: Net income attributable to noncontrolling interests included in continuing operations | (14.7) | (14.1) | (44.3) | (42.5) |
| Add: Interest on convertible debt, net of tax | 2.3 | — | 6.8 | — |
| Income from continuing operations attributable to HealthSouth common shareholders | 53.3 | 59.1 | 183.9 | 275.9 |
| (Loss) income from discontinued operations, net of tax, attributable to HealthSouth common shareholders | (0.9) | (0.9) | 2.8 | (1.2) |
| Net income attributable to HealthSouth common shareholders | \$52.4 | \$58.2 | \$186.7 | \$274.7 |
| Denominator: | | | | |
| Diluted weighted average common shares outstanding | 100.5 | 100.4 | 100.7 | 102.4 |
| Diluted earnings per share attributable to HealthSouth common shareholders: | | | | |
| Continuing operations | \$0.53 | \$0.59 | \$1.82 | \$2.69 |
| Discontinued operations | (0.01) | (0.01) | 0.03 | (0.01) |
| Net income | \$0.52 | \$0.58 | \$1.85 | \$2.68 |

HealthSouth Corporation and Subsidiaries
Notes to Condensed Consolidated Financial Statements

The following table sets forth the reconciliation between basic weighted average common shares outstanding and diluted weighted average common shares outstanding (in millions):

| | Three Months Ended | | Nine Months Ended | |
|---|--------------------|-------|-------------------|-------|
| | September 30, | | September 30, | |
| | 2014 | 2013 | 2014 | 2013 |
| Basic weighted average common shares outstanding | 86.5 | 86.2 | 86.8 | 88.7 |
| Convertible perpetual preferred stock | 3.2 | 11.6 | 3.2 | 11.6 |
| Convertible senior subordinated notes | 8.2 | — | 8.1 | — |
| Restricted stock awards, dilutive stock options, and restricted stock units | 2.6 | 2.6 | 2.6 | 2.1 |
| Diluted weighted average common shares outstanding | 100.5 | 100.4 | 100.7 | 102.4 |

Options to purchase approximately 0.1 million shares of common stock were outstanding as of September 30, 2014 and 2013, but were not included in the computation of diluted weighted-average shares because to do so would have been antidilutive.

On February 14, 2014, our board of directors approved an increase in our existing common stock repurchase authorization from \$200 million to \$250 million. The repurchase authorization does not require the repurchase of a specific number of shares, has an indefinite term, and is subject to termination at any time by our board of directors. During the nine months ended September 30, 2014, we repurchased 1.3 million shares of our common stock in the open market for \$43.1 million using cash on hand.

On February 14, 2014, our board of directors declared a cash dividend of \$0.18 per common share that was paid on April 15, 2014 to stockholders of record on April 1, 2014. On May 1, 2014, our board of directors declared a cash dividend of \$0.18 per common share that was paid on July 15, 2014 to stockholders of record on July 1, 2014. On July 17, 2014, our board of directors approved an increase in our quarterly dividend and declared a cash dividend of \$0.21 per common share paid on October 15, 2014 to stockholders of record on October 1, 2014. On October 21, 2014, our board of directors declared a cash dividend of \$0.21 per share, payable on January 15, 2015 to stockholders of record on January 2, 2015. As of September 30, 2014 and December 31, 2013, accrued common stock dividends of \$18.7 million and \$15.8 million were included in Accrued expenses and other current liabilities in our condensed consolidated balance sheet. Future dividend payments are subject to declaration by our board of directors.

As discussed more fully in Note 10, Convertible Perpetual Preferred Stock, to the consolidated financial statements accompanying the 2013 Form 10-K, the agreement underlying our preferred stock includes antidilutive protection that requires adjustments to the number of shares of common stock issuable upon conversion and the exercise price for common stock upon the occurrence of certain events, including payment of cash dividends on our common stock after a de minimis threshold. At issuance, the preferred stock had a conversion price of \$30.50 per share, which was equal to an initial conversion rate of 32.7869 shares of common stock per share of preferred stock. Additionally, our convertible notes (see Note 8, Long-term Debt, to the consolidated financial statements accompanying the 2013 Form 10 K) also include similar antidilutive protection that requires adjustments to the number of shares of common stock issuable upon conversion and the exercise price for common stock upon the occurrence of certain events, including payment of cash dividends on our common stock after a de minimis threshold. At issuance, the convertible notes had a conversion price of \$39.65 per share, which was equal to an initial conversion rate of 25.2194 shares per \$1,000 principal amount of the convertible notes. The payment of dividends beginning in October 2013 has triggered, from time to time, the antidilutive adjustment provisions of the preferred stock and convertible notes. As of October 2, 2014, the resulting exercise prices of the preferred stock and convertible notes were \$29.70 and \$38.82 per share, respectively, and the resulting conversion rates were 33.6700 and 25.7582 for each preferred share and for each \$1,000 principal amount of the convertible notes, respectively.

HealthSouth Corporation and Subsidiaries
Notes to Condensed Consolidated Financial Statements

In January 2004, we repaid our then-outstanding 3.25% Convertible Debentures using the net proceeds of a loan arranged by Credit Suisse First Boston. In connection with this transaction, we issued ten million warrants with an expiration date of January 16, 2014 to the lender to purchase shares of our common stock. The following table summarizes information relating to these warrants and their activity from December 31, 2013 through their expiration date (number of warrants in millions):

| | Number of Warrants | Weighted Average Exercise Price |
|---|-----------------------|------------------------------------|
| Common stock warrants outstanding as of December 31, 2013 | 2.9 | \$32.50 |
| Cashless exercise | (1.8 |) 32.16 |
| Cash exercise | (1.0 |) 32.16 |
| Expired | (0.1 |) 32.16 |
| Common stock warrants outstanding as of January 16, 2014 | — | |

The above exercises resulted in the issuance of 0.2 million shares of common stock during the nine months ended September 30, 2014. Cash exercises resulted in gross proceeds of \$6.3 million during the nine months ended September 30, 2014.

See Note 10, Convertible Perpetual Preferred Stock, and Note 17, Earnings per Common Share, to the consolidated financial statements accompanying the 2013 Form 10-K for additional information related to common stock, common stock warrants, and convertible perpetual preferred stock.

11. Contingencies and Other Commitments

We operate in a highly regulated and litigious industry. As a result, various lawsuits, claims, and legal and regulatory proceedings have been and can be expected to be instituted or asserted against us. The resolution of any such lawsuits, claims, or legal and regulatory proceedings could materially and adversely affect our financial position, results of operations, and cash flows in a given period.

Litigation By and Against Former Independent Auditor—

In March 2003, claims on behalf of HealthSouth were brought against Ernst & Young, LLP in a stockholder derivative lawsuit initially filed in the Circuit Court of Jefferson County, Alabama on August 28, 2002 and captioned Tucker v. Scrushy. The Tucker derivative litigation, including the claims against various other defendants and the \$2.9 billion judgment against Mr. Scrushy, our former chairman and chief executive officer, is more fully described in “Derivative Litigation” and “Litigation By and Against Former Independent Auditor” in Note 18, Contingencies and Other Commitments, to the consolidated financial statements accompanying the 2013 Form 10-K. The Tucker complaint alleged that from 1996 through 2002, when Ernst & Young served as our independent auditor, Ernst & Young acted recklessly and with gross negligence in performing its duties, and specifically that Ernst & Young failed to perform reviews and audits of our financial statements with due professional care as required by law and by its contractual agreements with us. The claims further alleged Ernst & Young either knew of or, in the exercise of due care, should have discovered and investigated the fraudulent and improper accounting practices being directed by certain officers and employees, and should have reported them to our board of directors and the audit committee. The claims sought compensatory and punitive damages, disgorgement of fees received from us by Ernst & Young, and attorneys’ fees and costs.

On March 18, 2005, Ernst & Young filed a lawsuit captioned Ernst & Young LLP v. HealthSouth Corp. in the Circuit Court of Jefferson County, Alabama. The complaint alleged we provided Ernst & Young with fraudulent management representation letters, financial statements, invoices, bank reconciliations, and journal entries in an effort to conceal accounting fraud. Ernst & Young claimed that as a result of our actions, Ernst & Young’s reputation had been injured and it incurred damages, expenses, and legal fees. On April 1, 2005, we answered Ernst & Young’s claims and asserted counterclaims related or identical to those asserted in the Tucker action. Upon Ernst & Young’s motion, the Alabama state court referred Ernst & Young’s claims and our counterclaims to arbitration pursuant to a clause in the engagement agreements between HealthSouth

HealthSouth Corporation and Subsidiaries
Notes to Condensed Consolidated Financial Statements

and Ernst & Young. In August 2006, we and the derivative plaintiffs agreed to jointly prosecute the claims against Ernst & Young in arbitration.

The trial phase of the arbitration process began on July 12, 2010 before a three-person arbitration panel selected under rules of the American Arbitration Association (the "AAA"). On December 18, 2012, the AAA panel granted Ernst & Young's motion to dismiss our claims on the grounds that HealthSouth was not permitted to pursue its claims since certain of its former officers and employees committed fraudulent acts. The panel also denied and dismissed Ernst & Young's claims against us. On December 18, 2012, we, together with the stockholder derivative plaintiffs, filed a notice of appeal of the panel's decision in the Circuit Court of Jefferson County, Alabama. On December 28, 2012, we filed a motion to vacate the decision. We asserted that the panel's decision was contrary to the Federal Arbitration Act and the duties of a public accounting firm to its corporate clients, and that the arbitrators exceeded their authority by entering an award contrary to Alabama law. On April 25, 2013, the court denied our motion to vacate. On June 4, 2013, we filed a notice of appeal to the Supreme Court of Alabama seeking review of the circuit court's denial of our motion to vacate the arbitration panel's decision. On June 13, 2014, the Supreme Court of Alabama affirmed the decision by the circuit court. On June 27, 2014, we filed an application for rehearing with the Supreme Court of Alabama. On August 22, 2014, the Supreme Court of Alabama denied our application, and as a result, we consider this litigation matter concluded.

General Medicine Action—

On August 16, 2004, General Medicine, P.C. filed a lawsuit against us captioned General Medicine, P.C. v. HealthSouth Corp. seeking the recovery of allegedly fraudulent transfers involving assets of Horizon/CMS Healthcare Corporation, a former subsidiary of HealthSouth. The lawsuit is pending in the Circuit Court of Jefferson County, Alabama (the "Alabama Action").

General Medicine's underlying claim against Horizon/CMS originates from a services contract entered into in 1995 between General Medicine and Horizon/CMS whereby General Medicine agreed to provide medical director services to skilled nursing facilities owned by Horizon/CMS for a term of three years. Horizon/CMS terminated the agreement for cause six months after it was executed, and General Medicine then initiated a lawsuit against Horizon/CMS in the United States District Court for the Eastern District of Michigan in 1996 (the "Michigan Action"). General Medicine's complaint in the Michigan Action alleged that Horizon/CMS breached the services contract by wrongfully terminating General Medicine. We acquired Horizon/CMS in 1997 and sold it to Meadowbrook Healthcare, Inc. in 2001 pursuant to a stock purchase agreement. In 2004, Meadowbrook, without the knowledge of HealthSouth, consented to the entry of a final judgment in the Michigan Action in favor of General Medicine against Horizon/CMS for the alleged wrongful termination of the contract with General Medicine in the amount of \$376 million (the "Consent Judgment"). The \$376 million damages figure was unilaterally selected by General Medicine and was not tested or opposed by Meadowbrook. Additionally, the settlement agreement (the "Settlement") used as the basis for the Consent Judgment provided that Meadowbrook would pay only \$300,000 to General Medicine to settle the Michigan Action and that General Medicine would seek to recover the remaining balance of the Consent Judgment solely from us. We were not a party to the Michigan Action, the Settlement negotiated by Meadowbrook, or the Consent Judgment.

The complaint filed by General Medicine against us in the Alabama Action alleges that while Horizon/CMS was our wholly owned subsidiary, General Medicine was an existing creditor of Horizon/CMS by virtue of the breach of contract claim underlying the Settlement. The complaint also alleges we caused Horizon/CMS to transfer its assets to us for less than a reasonably equivalent value or, in the alternative, with the actual intent to defraud creditors of Horizon/CMS, including General Medicine, in violation of the Alabama Uniform Fraudulent Transfer Act. General Medicine further alleges in its amended complaint that we are liable for the Consent Judgment despite not being a party to it because as Horizon/CMS's parent we failed to observe corporate formalities in our operation and ownership of Horizon/CMS, misused our control of Horizon/CMS, stripped assets from Horizon/CMS, and engaged in other conduct which amounted to a fraud on Horizon/CMS's creditors. General Medicine has requested relief including recovery of the unpaid amount of the Consent Judgment, the avoidance of the subject transfers of assets, attachment of the assets transferred to us, appointment of a receiver over the transferred properties, and a monetary judgment for the value of properties transferred.

We have denied liability to General Medicine and asserted defenses and a counterclaim against General Medicine that the Consent Judgment is the product of collusion by General Medicine and Meadowbrook. Consequently, we assert that the Consent Judgment is not evidence of a legitimate debt owed by Horizon/CMS to General Medicine that is collectible from HealthSouth under any theory of liability.

HealthSouth Corporation and Subsidiaries
Notes to Condensed Consolidated Financial Statements

In 2008, after we obtained discovery concerning the circumstances that led to the entry of the Consent Judgment, we filed a motion in the Michigan Action asking the court to set aside the Consent Judgment on grounds that it was the product of fraud on the court and collusion by the parties. On May 21, 2009, the court granted our motion to set aside the Consent Judgment on grounds that it was the product of fraud on the court. On March 9, 2010, General Medicine filed an appeal of the court's decision to the Sixth Circuit Court of Appeals. The parties agreed to a voluntary stay of the Alabama Action pending the outcome of General Medicine's appeal to the Sixth Circuit Court of Appeals. On April 10, 2012, the Sixth Circuit Court of Appeals reversed the lower court's ruling and reinstated the Consent Judgment. Due to the conclusion of the appeal in the Michigan Action, General Medicine requested reactivation of the Alabama Action in the Circuit Court of Jefferson County, Alabama. On January 10, 2013, we filed a motion for partial summary judgment in the Alabama Action seeking a declaration that the Consent Judgment obtained by General Medicine is not enforceable against us because, among other reasons, it was the result of collusion. On February 27, 2013, the court denied our motion. The court also indicated it concurred with the Sixth Circuit Court of Appeals that the Consent Judgment did nothing more than establish Horizon/CMS's liability to General Medicine and did not establish the amount of General Medicine's damages claim against Horizon/CMS or the merits of General Medicine's separate fraudulent conveyance claims against HealthSouth.

On January 9, 2014 and on February 18, 2014, the court in the Alabama Action entered rulings based on General Medicine's stipulation that it would not rely on the Consent Judgment to prove the amount of its damages claim against Horizon/CMS, which rulings together provided that the \$376 million damages figure contained in the Consent Judgment is not admissible at trial and that the issue of collusion with respect to the amount of the Consent Judgment is now moot. Instead of relying on the Consent Judgment to prove damages against Horizon/CMS, General Medicine will be required to prove the amount of any damages it has against Horizon/CMS. General Medicine did, however, indicate it would rely on the Consent Judgment to prove its status as a creditor of Horizon/CMS and that Horizon/CMS is indebted to General Medicine for breaching the 1995 services contract. On March 31, 2014, General Medicine filed a motion seeking partial summary judgment and requesting dismissal of our defenses and counterclaim which allege the Consent Judgment was the product of collusion. In opposition to the motion, we argued the Consent Judgment is collusive in its entirety, not just with respect to the \$376 million damages figure, and there has never been a valid adjudication that Horizon/CMS breached its 1995 services contract with General Medicine or that Horizon/CMS is indebted to General Medicine for any amount. On July 15, 2014, the court issued an order denying General Medicine's motion for partial summary judgment.

On May 3, 2014, the Consent Judgment expired under applicable Michigan law without renewal by General Medicine. Based on the expiration, on July 23, 2014, we filed a motion for summary judgment requesting dismissal of General Medicine's lawsuit against us on grounds that General Medicine is no longer a "creditor" of Horizon/CMS, which is an essential element of the fraudulent transfer and alter ego claims against us, and that General Medicine's lawsuit against us is now moot. On August 13, 2014, the court denied our motion for summary judgment.

The trial began on September 15, 2014. On September 16, 2014, the court issued a provisional ruling precluding us from offering any evidence at trial that the Consent Judgment was the product of collusion by General Medicine and Meadowbrook, unless General Medicine opens the door by introducing evidence of the \$376 million amount of the Consent Judgment. On September 18, 2014, the court granted General Medicine's motion for a mistrial based on certain statements made during opening statements. The Alabama Action has been reset for trial beginning on March 9, 2015.

On September 24, 2014, we filed a petition for writ of mandamus with the Supreme Court of Alabama requesting that it review the trial court's August 13, 2014 order denying our motion for summary judgment. A petition for writ of mandamus is a discretionary appeal, rather than an appeal as a matter of right. If the supreme court agrees to hear our petition, it will direct the parties to submit briefs on the merits and will most likely stay the March 9, 2015 trial until it renders a decision. If it does not agree to hear our petition, then the case is expected to proceed to trial on that date. We intend to vigorously defend ourselves against General Medicine's claims. Based on the stage of litigation, review of the current facts and circumstances as we understand them, the nature of the underlying claim, the results of the proceedings to date, and the nature and scope of the defense we continue to mount, we do not believe an adverse

judgment or settlement is probable in this matter, and it is also not possible to estimate the amount of loss, if any, or range of possible loss that might result from an adverse judgment or settlement of this case.

HealthSouth Corporation and Subsidiaries
Notes to Condensed Consolidated Financial Statements

Other Litigation—

We have been named as a defendant in a lawsuit filed March 28, 2003 by several individual stockholders in the Circuit Court of Jefferson County, Alabama, captioned Nichols v. HealthSouth Corp. The plaintiffs allege that we, some of our former officers, and our former investment bank engaged in a scheme to overstate and misrepresent our earnings and financial position. The plaintiffs are seeking compensatory and punitive damages. This case was consolidated with the Tucker case for discovery and other pretrial purposes and was stayed in the Circuit Court on August 8, 2005. The plaintiffs filed an amended complaint on November 9, 2010 to which we responded with a motion to dismiss filed on December 22, 2010. During a hearing on February 24, 2012, plaintiffs' counsel indicated his intent to dismiss certain claims against us. Instead, on March 9, 2012, the plaintiffs amended their complaint to include additional securities fraud claims against HealthSouth and add several former officers to the lawsuit. On September 12, 2012, the plaintiffs further amended their complaint to request certification as a class action. One of those named officers has repeatedly attempted to remove the case to federal district court, most recently on December 11, 2012. We filed our latest motion to remand the case back to state court on January 10, 2013. On September 27, 2013, the federal court remanded the case back to state court. We intend to vigorously defend ourselves in this case. Based on the stage of litigation, review of the current facts and circumstances as we understand them, the nature of the underlying claim, the results of the proceedings to date, and the nature and scope of the defense we continue to mount, we do not believe an adverse judgment or settlement is probable in this matter, and it is also not possible to estimate the amount of loss, if any, or range of possible loss that might result from an adverse judgment or settlement of this case.

Governmental Inquiries and Investigations—

On June 24, 2011, we received a document subpoena addressed to HealthSouth Hospital of Houston, a long-term acute care hospital ("LTCH") we closed in August 2011, and issued from the Dallas, Texas office of the U.S. Department of Health and Human Services, Office of the Inspector General (the "HHS-OIG"). The subpoena stated it was in connection with an investigation of possible false or otherwise improper claims submitted to Medicare and Medicaid and requested documents and materials relating to patient admissions, length of stay, and discharge matters at this closed LTCH. We furnished the documents requested and have heard nothing from HHS-OIG since December 2012.

On March 4, 2013, we received document subpoenas from an office of the HHS-OIG addressed to four of our hospitals. Those subpoenas also requested complete copies of medical records for 100 patients treated at each of those hospitals between September 2008 and June 2012. The investigation is being conducted by the United States Department of Justice (the "DOJ"). On April 24, 2014, we received document subpoenas relating to an additional seven of our hospitals. The new subpoenas reference substantially similar investigation subject matter as the original subpoenas and request materials from the period January 2008 through December 2013. Two of the four hospitals addressed in the original set of subpoenas have received supplemental subpoenas to cover this new time period. The new subpoenas do not include requests for specific patient files, but it is expected that such requests will be made for the new group of hospitals.

All of the subpoenas are in connection with an investigation of alleged improper or fraudulent claims submitted to Medicare and Medicaid and request documents and materials relating to practices, procedures, protocols and policies, of certain pre- and post-admissions activities at these hospitals including, among other things, marketing functions, pre-admission screening, post-admission physician evaluations, patient assessment instruments, individualized patient plans of care, and compliance with the Medicare 60% rule. Under the Medicare rule commonly referred to as the "60% rule," an inpatient rehabilitation hospital must treat 60% or more of its patients from at least one of a specified list of medical conditions in order to be reimbursed at the inpatient rehabilitation hospital payment rates, rather than at the lower acute care hospital payment rates.

We are cooperating fully with the DOJ in connection with these subpoenas and are currently unable to predict the timing or outcome of the related investigations.

Other Matters—

The False Claims Act, 18 U.S.C. § 287, allows private citizens, called “relators,” to institute civil proceedings alleging violations of the False Claims Act. These qui tam cases are generally sealed by the court at the time of filing. The only parties typically privy to the information contained in the complaint are the relator, the federal government, and the presiding court. It is possible that qui tam lawsuits have been filed against us and that those suits remain under seal or that we are unaware of such

HealthSouth Corporation and Subsidiaries
Notes to Condensed Consolidated Financial Statements

filings or prevented by existing law or court order from discussing or disclosing the filing of such suits. We may be subject to liability under one or more undisclosed qui tam cases brought pursuant to the False Claims Act.

It is our obligation as a participant in Medicare and other federal healthcare programs to routinely conduct audits and reviews of the accuracy of our billing systems and other regulatory compliance matters. As a result of these reviews, we have made, and will continue to make, disclosures to the HHS-OIG and the United States Centers for Medicare and Medicaid Services relating to amounts we suspect represent over-payments from these programs, whether due to inaccurate billing or otherwise. Some of these disclosures have resulted in, or may result in, HealthSouth refunding amounts to Medicare or other federal healthcare programs.

12. Condensed Consolidating Financial Information

The accompanying condensed consolidating financial information has been prepared and presented pursuant to SEC Regulation S-X, Rule 3-10, "Financial Statements of Guarantors and Issuers of Guaranteed Securities Registered or Being Registered." Each of the subsidiary guarantors is 100% owned by HealthSouth, and all guarantees are full and unconditional and joint and several, subject to certain customary conditions for release. HealthSouth's investments in its consolidated subsidiaries, as well as guarantor subsidiaries' investments in nonguarantor subsidiaries and nonguarantor subsidiaries' investments in guarantor subsidiaries, are presented under the equity method of accounting with the related investment presented within the line items Intercompany receivable and Intercompany payable in the accompanying condensed consolidating balance sheets.

The terms of our credit agreement allow us to declare and pay cash dividends on our common stock so long as: (1) we are not in default under our credit agreement and (2) our senior secured leverage ratio (as defined in our credit agreement) remains less than or equal to 1.75x. The terms of our senior note indenture allow us to declare and pay cash dividends on our common stock so long as (1) we are not in default, (2) the consolidated coverage ratio (as defined in the indenture) exceeds 2x or we are otherwise allowed under the indenture to incur debt, and (3) we have capacity under the indenture's restricted payments covenant to declare and pay dividends. See Note 8, Long-term Debt, to the consolidated financial statements accompanying the 2013 Form 10-K.

As described in Note 10, Convertible Perpetual Preferred Stock, to the consolidated financial statements accompanying the 2013 Form 10-K, our preferred stock generally provides for the payment of cash dividends, subject to certain limitations. Our credit agreement and our senior note indenture do not limit the payment of dividends on the preferred stock.

Periodically, certain wholly owned subsidiaries of HealthSouth make dividends or distributions of available cash and/or intercompany receivable balances to their parents. In addition, HealthSouth makes contributions to certain wholly owned subsidiaries. When made, these dividends, distributions, and contributions impact the Intercompany receivable, Intercompany payable, and HealthSouth shareholders' equity line items in the accompanying condensed consolidating balance sheet but have no impact on the consolidated financial statements of HealthSouth Corporation.

HealthSouth Corporation and Subsidiaries
Notes to Condensed Consolidated Financial Statements
Condensed Consolidating Statement of Operations

| | Three Months Ended September 30, 2014 | | | | |
|---|--|------------------------|---------------------------|---------------------|--------------------------|
| | HealthSouth Corporation (In Millions) | Guarantor Subsidiaries | Nonguarantor Subsidiaries | Eliminating Entries | HealthSouth Consolidated |
| Net operating revenues | \$4.0 | \$424.5 | \$191.2 | \$(22.8) |) \$596.9 |
| Less: Provision for doubtful accounts | — | (5.7) | (2.5) | — | (8.2) |
| Net operating revenues less provision for doubtful accounts | 4.0 | 418.8 | 188.7 | (22.8) |) 588.7 |
| Operating expenses: | | | | | |
| Salaries and benefits | 4.1 | 197.9 | 91.8 | (3.8) |) 290.0 |
| Other operating expenses | 5.0 | 62.0 | 31.8 | (9.4) |) 89.4 |
| Occupancy costs | 1.1 | 14.5 | 4.3 | (9.6) |) 10.3 |
| Supplies | 0.1 | 18.6 | 7.9 | — | 26.6 |
| General and administrative expenses | 27.5 | — | — | — | 27.5 |
| Depreciation and amortization | 2.3 | 18.2 | 6.9 | — | 27.4 |
| Professional fees—accounting, tax, and legal | 4.0 | — | — | — | 4.0 |
| Total operating expenses | 44.1 | 311.2 | 142.7 | (22.8) |) 475.2 |
| Interest expense and amortization of debt discounts and fees | 25.7 | 1.7 | 0.7 | (0.3) |) 27.8 |
| Other income | 0.1 | — | (0.6) |) 0.3 | (0.2) |
| Equity in net income of nonconsolidated affiliates | — | (1.9) | — | — | (1.9) |
| Equity in net income of consolidated affiliates | (62.6) |) (7.2) |) — | 69.8 | — |
| Management fees | (26.8) |) 20.4 | 6.4 | — | — |
| Income from continuing operations before income tax (benefit) expense | 23.5 | 94.6 | 39.5 | (69.8) |) 87.8 |
| Provision for income tax (benefit) expense | (27.5) |) 39.2 | 10.4 | — | 22.1 |
| Income from continuing operations | 51.0 | 55.4 | 29.1 | (69.8) |) 65.7 |
| Loss from discontinued operations, net of tax | (0.9) |) — | — | — | (0.9) |
| Net Income | 50.1 | 55.4 | 29.1 | (69.8) |) 64.8 |
| Less: Net income attributable to noncontrolling interests | — | — | (14.7) |) — | (14.7) |
| Net income attributable to HealthSouth | \$50.1 | \$55.4 | \$14.4 | \$(69.8) |) \$50.1 |
| Comprehensive income | \$50.0 | \$55.4 | \$29.1 | \$(69.8) |) \$64.7 |
| Comprehensive income attributable to HealthSouth | \$50.0 | \$55.4 | \$14.4 | \$(69.8) |) \$50.0 |

Edgar Filing: HEALTHSOUTH CORP - Form 10-Q

HealthSouth Corporation and Subsidiaries
Notes to Condensed Consolidated Financial Statements
Condensed Consolidating Statement of Operations

| | Three Months Ended September 30, 2013 | | | | HealthSouth Consolidated |
|---|--|------------------------|---------------------------|---------------------|--------------------------|
| | HealthSouth Corporation (In Millions) | Guarantor Subsidiaries | Nonguarantor Subsidiaries | Eliminating Entries | |
| Net operating revenues | \$3.0 | \$399.7 | \$179.2 | \$(17.9) |) \$564.0 |
| Less: Provision for doubtful accounts | — | (5.6) | (2.4) | — | (8.0) |
| Net operating revenues less provision for doubtful accounts | 3.0 | 394.1 | 176.8 | (17.9) |) 556.0 |
| Operating expenses: | | | | | |
| Salaries and benefits | 0.1 | 187.4 | 85.6 | (3.6) |) 269.5 |
| Other operating expenses | 3.2 | 59.6 | 27.9 | (8.5) |) 82.2 |
| Occupancy costs | 1.0 | 12.0 | 4.5 | (5.8) |) 11.7 |
| Supplies | — | 17.9 | 7.6 | — | 25.5 |
| General and administrative expenses | 28.8 | — | — | — | 28.8 |
| Depreciation and amortization | 2.2 | 16.7 | 5.4 | — | 24.3 |
| Government, class action, and related settlements | (21.3) |) — | — | — | (21.3) |
| Professional fees—accounting, tax, and legal | 4.2 | — | — | — | 4.2 |
| Total operating expenses | 18.2 | 293.6 | 131.0 | (17.9) |) 424.9 |
| Interest expense and amortization of debt discounts and fees | 22.4 | 2.4 | 0.8 | (0.3) |) 25.3 |
| Other income | (0.4) |) — | (0.5) |) 0.3 | (0.6) |
| Equity in net income of nonconsolidated affiliates | (0.3) |) (1.7) |) — | — | (2.0) |
| Equity in net income of consolidated affiliates | (59.7) |) (5.5) |) — | 65.2 | — |
| Management fees | (25.2) |) 19.2 | 6.0 | — | — |
| Income from continuing operations before income tax (benefit) expense | 48.0 | 86.1 | 39.5 | (65.2) |) 108.4 |
| Provision for income tax (benefit) expense | (10.3) |) 34.9 | 10.6 | — | 35.2 |
| Income from continuing operations | 58.3 | 51.2 | 28.9 | (65.2) |) 73.2 |
| Loss from discontinued operations, net of tax | (0.1) |) (0.4) |) (0.4) |) — | (0.9) |
| Net Income | 58.2 | 50.8 | 28.5 | (65.2) |) 72.3 |
| Less: Net income attributable to noncontrolling interests | — | — | (14.1) |) — | (14.1) |
| Net income attributable to HealthSouth | \$58.2 | \$50.8 | \$14.4 | \$(65.2) |) \$58.2 |
| Comprehensive income | \$58.3 | \$50.8 | \$28.5 | \$(65.2) |) \$72.4 |
| Comprehensive income attributable to HealthSouth | \$58.3 | \$50.8 | \$14.4 | \$(65.2) |) \$58.3 |

Edgar Filing: HEALTHSOUTH CORP - Form 10-Q

HealthSouth Corporation and Subsidiaries
Notes to Condensed Consolidated Financial Statements
Condensed Consolidating Statement of Operations

| | Nine Months Ended September 30, 2014 | | | | HealthSouth Consolidated | |
|---|--|------------------------|---------------------------|---------------------|--------------------------|---|
| | HealthSouth Corporation (In Millions) | Guarantor Subsidiaries | Nonguarantor Subsidiaries | Eliminating Entries | | |
| Net operating revenues | \$ 11.5 | \$ 1,286.4 | \$ 561.7 | \$(67.1 |) \$ 1,792.5 | |
| Less: Provision for doubtful accounts | — | (17.6 |) (7.4 |) — | (25.0 |) |
| Net operating revenues less provision for doubtful accounts | 11.5 | 1,268.8 | 554.3 | (67.1 |) 1,767.5 | |
| Operating expenses: | | | | | | |
| Salaries and benefits | 15.9 | 590.2 | 266.6 | (11.3 |) 861.4 | |
| Other operating expenses | 15.0 | 182.1 | 90.0 | (26.9 |) 260.2 | |
| Occupancy costs | 3.1 | 43.4 | 13.5 | (28.9 |) 31.1 | |
| Supplies | — | 57.9 | 24.1 | — | 82.0 | |
| General and administrative expenses | 88.4 | — | — | — | 88.4 | |
| Depreciation and amortization | 7.4 | 54.1 | 18.7 | — | 80.2 | |
| Government, class action, and related settlements | (0.8 |) — | — | — | (0.8 |) |
| Professional fees—accounting, tax, and legal | 7.6 | — | — | — | 7.6 | |
| Total operating expenses | 136.6 | 927.7 | 412.9 | (67.1 |) 1,410.1 | |
| Interest expense and amortization of debt discounts and fees | 76.3 | 5.9 | 2.1 | (0.8 |) 83.5 | |
| Other income | (0.3 |) (28.4 |) (2.2 |) 0.8 | (30.1 |) |
| Equity in net income of nonconsolidated affiliates | — | (8.8 |) — | — | (8.8 |) |
| Equity in net income of consolidated affiliates | (233.9 |) (21.3 |) — | 255.2 | — | |
| Management fees | (80.7 |) 61.6 | 19.1 | — | — | |
| Income from continuing operations before income tax (benefit) expense | 113.5 | 332.1 | 122.4 | (255.2 |) 312.8 | |
| Provision for income tax (benefit) expense | (63.5 |) 122.0 | 32.9 | — | 91.4 | |
| Income from continuing operations | 177.0 | 210.1 | 89.5 | (255.2 |) 221.4 | |
| Income (loss) from discontinued operations, net of tax | 2.9 | — | (0.1 |) — | 2.8 | |
| Net Income | 179.9 | 210.1 | 89.4 | (255.2 |) 224.2 | |
| Less: Net income attributable to noncontrolling interests | — | — | (44.3 |) — | (44.3 |) |
| Net income attributable to HealthSouth | \$ 179.9 | \$ 210.1 | \$ 45.1 | \$(255.2 |) \$ 179.9 | |
| Comprehensive income | \$ 179.9 | \$ 210.1 | \$ 89.4 | \$(255.2 |) \$ 224.2 | |
| Comprehensive income attributable to HealthSouth | \$ 179.9 | \$ 210.1 | \$ 45.1 | \$(255.2 |) \$ 179.9 | |

Edgar Filing: HEALTHSOUTH CORP - Form 10-Q

HealthSouth Corporation and Subsidiaries
Notes to Condensed Consolidated Financial Statements
Condensed Consolidating Statement of Operations

| | Nine Months Ended September 30, 2013 | | | | |
|---|--|------------------------|---------------------------|---------------------|--------------------------|
| | HealthSouth Corporation (In Millions) | Guarantor Subsidiaries | Nonguarantor Subsidiaries | Eliminating Entries | HealthSouth Consolidated |
| Net operating revenues | \$9.0 | \$1,215.1 | \$529.2 | \$(52.2) |) \$1,701.1 |
| Less: Provision for doubtful accounts | — | (15.6) |) (6.8) |) — | (22.4) |
| Net operating revenues less provision for doubtful accounts | 9.0 | 1,199.5 | 522.4 | (52.2) |) 1,678.7 |
| Operating expenses: | | | | | |
| Salaries and benefits | 13.5 | 565.7 | 249.4 | (10.9) |) 817.7 |
| Other operating expenses | 9.1 | 177.4 | 79.8 | (25.0) |) 241.3 |
| Occupancy costs | 3.1 | 35.9 | 13.1 | (16.3) |) 35.8 |
| Supplies | — | 55.1 | 23.2 | — | 78.3 |
| General and administrative expenses | 88.5 | — | — | — | 88.5 |
| Depreciation and amortization | 6.5 | 47.8 | 15.2 | — | 69.5 |
| Government, class action, and related settlements | (23.3) |) — | — | — | (23.3) |
| Professional fees—accounting, tax, and legal | 7.8 | — | — | — | 7.8 |
| Total operating expenses | 105.2 | 881.9 | 380.7 | (52.2) |) 1,315.6 |
| Interest expense and amortization of debt discounts and fees | 66.8 | 5.7 | 2.4 | (1.0) |) 73.9 |
| Other income | (0.7) |) (0.8) |) (2.7) |) 1.0 | (3.2) |
| Equity in net income of nonconsolidated affiliates | (2.5) |) (5.7) |) — | — | (8.2) |
| Equity in net income of consolidated affiliates | (243.3) |) (22.3) |) — | 265.6 | — |
| Management fees | (76.6) |) 58.7 | 17.9 | — | — |
| Income from continuing operations before income tax (benefit) expense | 160.1 | 282.0 | 124.1 | (265.6) |) 300.6 |
| Provision for income tax (benefit) expense | (114.5) |) 69.7 | 27.0 | — | (17.8) |
| Income from continuing operations | 274.6 | 212.3 | 97.1 | (265.6) |) 318.4 |
| Income (loss) from discontinued operations, net of tax | 0.1 | (0.1) |) (1.2) |) — | (1.2) |
| Net Income | 274.7 | 212.2 | 95.9 | (265.6) |) 317.2 |
| Less: Net income attributable to noncontrolling interests | — | — | (42.5) |) — | (42.5) |
| Net income attributable to HealthSouth | \$274.7 | \$212.2 | \$53.4 | \$(265.6) |) \$274.7 |
| Comprehensive income | \$273.1 | \$212.2 | \$95.9 | \$(265.6) |) \$315.6 |
| Comprehensive income attributable to HealthSouth | \$273.1 | \$212.2 | \$53.4 | \$(265.6) |) \$273.1 |

HealthSouth Corporation and Subsidiaries
Notes to Condensed Consolidated Financial Statements
Condensed Consolidating Balance Sheet

| | As of September 30, 2014 | | | | |
|--|---|---------------------------|------------------------------|------------------------|-----------------------------|
| | HealthSouth Corporation (In Millions) | Guarantor Subsidiaries | Nonguarantor Subsidiaries | Eliminating Entries | HealthSouth Consolidated |
| Assets | | | | | |
| Current assets: | | | | | |
| Cash and cash equivalents | \$266.5 | \$1.5 | 4.3 | \$— | \$272.3 |
| Accounts receivable, net | — | 186.1 | 75.5 | — | 261.6 |
| Deferred income tax assets | 85.5 | 34.5 | 18.9 | — | 138.9 |
| Other current assets | 40.4 | 14.1 | 91.2 | (35.5) |) 110.2 |
| Total current assets | 392.4 | 236.2 | 189.9 | (35.5) |) 783.0 |
| Property and equipment, net | 13.6 | 753.5 | 227.5 | — | 994.6 |
| Goodwill | — | 279.6 | 212.1 | — | 491.7 |
| Intangible assets, net | 12.9 | 46.2 | 40.8 | — | 99.9 |
| Deferred income tax assets | 203.4 | 24.5 | 27.4 | — | 255.3 |
| Other long-term assets | 74.5 | 35.3 | 59.7 | — | 169.5 |
| Intercompany receivable | 1,562.7 | — | — | (1,562.7) |) — |
| Total assets | \$2,259.5 | \$1,375.3 | \$757.4 | \$(1,598.2) |) \$2,794.0 |
| Liabilities and Shareholders' Equity | | | | | |
| Current liabilities: | | | | | |
| Current portion of long-term debt | \$217.7 | \$4.1 | \$4.2 | \$(17.5) |) 208.5 |
| Accounts payable | 8.8 | 33.0 | 13.0 | — | 54.8 |
| Accrued expenses and other current liabilities | 121.3 | 73.0 | 75.1 | (18.0) |) 251.4 |
| Total current liabilities | 347.8 | 110.1 | 92.3 | (35.5) |) 514.7 |
| Long-term debt, net of current portion | 1,324.3 | 85.0 | 32.1 | — | 1,441.4 |
| Other long-term liabilities | 44.6 | 12.5 | 82.6 | — | 139.7 |
| Intercompany payable | — | 431.9 | 212.5 | (644.4) |) — |
| | 1,716.7 | 639.5 | 419.5 | (679.9) |) 2,095.8 |
| Commitments and contingencies | | | | | |
| Convertible perpetual preferred stock | 93.2 | — | — | — | 93.2 |
| Redeemable noncontrolling interests | — | — | 12.2 | — | 12.2 |
| Shareholders' equity: | | | | | |
| HealthSouth shareholders' equity | 449.6 | 735.8 | 182.5 | (918.3) |) 449.6 |
| Noncontrolling interests | — | — | 143.2 | — | 143.2 |
| Total shareholders' equity | 449.6 | 735.8 | 325.7 | (918.3) |) 592.8 |
| Total liabilities and shareholders' equity | \$2,259.5 | \$1,375.3 | \$757.4 | \$(1,598.2) |) \$2,794.0 |

Edgar Filing: HEALTHSOUTH CORP - Form 10-Q

HealthSouth Corporation and Subsidiaries
Notes to Condensed Consolidated Financial Statements
Condensed Consolidating Balance Sheet

| | As of December 31, 2013 | | | | |
|--|--|------------------------|---------------------------|---------------------|--------------------------|
| | HealthSouth Corporation (In Millions) | Guarantor Subsidiaries | Nonguarantor Subsidiaries | Eliminating Entries | HealthSouth Consolidated |
| Assets | | | | | |
| Current assets: | | | | | |
| Cash and cash equivalents | \$60.5 | \$2.3 | \$1.7 | \$— | \$64.5 |
| Accounts receivable, net | — | 184.7 | 77.1 | — | 261.8 |
| Deferred income tax assets | 85.5 | 34.5 | 19.0 | — | 139.0 |
| Other current assets | 37.0 | 15.8 | 80.8 | (18.5) | 115.1 |
| Total current assets | 183.0 | 237.3 | 178.6 | (18.5) | 580.4 |
| Property and equipment, net | 16.3 | 698.5 | 195.7 | — | 910.5 |
| Goodwill | — | 279.6 | 177.3 | — | 456.9 |
| Intangible assets, net | 18.1 | 49.6 | 20.5 | — | 88.2 |
| Deferred income tax assets | 288.8 | 24.5 | 41.0 | — | 354.3 |
| Other long-term assets | 64.6 | 27.1 | 52.4 | — | 144.1 |
| Intercompany receivable | 1,438.8 | — | — | (1,438.8) | — |
| Total assets | \$2,009.6 | \$1,316.6 | \$665.5 | \$(1,457.3) | \$2,534.4 |
| Liabilities and Shareholders' Equity | | | | | |
| Current liabilities: | | | | | |
| Current portion of long-term debt | \$19.4 | \$3.8 | \$6.6 | \$(17.5) | \$12.3 |
| Accounts payable | 15.1 | 32.6 | 14.2 | — | 61.9 |
| Accrued expenses and other current liabilities | 111.1 | 67.2 | 60.1 | (1.0) | 237.4 |
| Total current liabilities | 145.6 | 103.6 | 80.9 | (18.5) | 311.6 |
| Long-term debt, net of current portion | 1,381.7 | 88.1 | 35.4 | — | 1,505.2 |
| Other long-term liabilities | 44.5 | 17.4 | 80.3 | — | 142.2 |
| Intercompany payable | — | 299.2 | 228.9 | (528.1) | — |
| | 1,571.8 | 508.3 | 425.5 | (546.6) | 1,959.0 |
| Commitments and contingencies | | | | | |
| Convertible perpetual preferred stock | 93.2 | — | — | — | 93.2 |
| Redeemable noncontrolling interests | — | — | 13.5 | — | 13.5 |
| Shareholders' equity: | | | | | |
| HealthSouth shareholders' equity | 344.6 | 808.3 | 102.4 | (910.7) | 344.6 |
| Noncontrolling interests | — | — | 124.1 | — | 124.1 |
| Total shareholders' equity | 344.6 | 808.3 | 226.5 | (910.7) | 468.7 |
| Total liabilities and shareholders' equity | \$2,009.6 | \$1,316.6 | \$665.5 | \$(1,457.3) | \$2,534.4 |

Edgar Filing: HEALTHSOUTH CORP - Form 10-Q

HealthSouth Corporation and Subsidiaries
Notes to Condensed Consolidated Financial Statements
Condensed Consolidating Statement of Cash Flows

| | Nine Months Ended September 30, 2014 | | | | | |
|---|--|------------------------|---------------------------|---------------------|--------------------------|---|
| | HealthSouth Corporation (In Millions) | Guarantor Subsidiaries | Nonguarantor Subsidiaries | Eliminating Entries | HealthSouth Consolidated | |
| Net cash provided by operating activities | \$53.5 | \$206.9 | \$114.3 | \$— | \$374.7 | |
| Cash flows from investing activities: | | | | | | |
| Purchases of property and equipment | (11.9 |) (97.9 |) (24.1 |) — | (133.9 |) |
| Capitalized software costs | (4.1 |) (1.5 |) (7.0 |) — | (12.6 |) |
| Acquisition of business, net of cash acquired | — | — | (15.9 |) — | (15.9 |) |
| Proceeds from sale of restricted investments | — | — | 0.3 | — | 0.3 | |
| Purchase of restricted investments | — | — | (2.5 |) — | (2.5 |) |
| Other | 1.0 | 1.3 | — | — | 2.3 | |
| Net cash used in investing activities | (15.0 |) (98.1 |) (49.2 |) — | (162.3 |) |
| Cash flows from financing activities: | | | | | | |
| Proceeds from bond issuance | 175.0 | — | — | — | 175.0 | |
| Borrowings on revolving credit facility | 65.0 | — | — | — | 65.0 | |
| Payments on revolving credit facility | (110.0 |) — | — | — | (110.0 |) |
| Repurchases of common stock, including fees and expenses | (43.1 |) — | — | — | (43.1 |) |
| Dividends paid on common stock | (47.4 |) — | — | — | (47.4 |) |
| Dividends paid on convertible perpetual preferred stock | (4.7 |) — | — | — | (4.7 |) |
| Distributions paid to noncontrolling interests of consolidated affiliates | — | — | (39.6 |) — | (39.6 |) |
| Other | 8.7 | (3.0 |) (5.5 |) — | 0.2 | |
| Change in intercompany advances | 124.0 | (106.6 |) (17.4 |) — | — | |
| Net cash provided by (used in) financing activities | 167.5 | (109.6 |) (62.5 |) — | (4.6 |) |
| Increase (decrease) in cash and cash equivalents | 206.0 | (0.8 |) 2.6 | — | 207.8 | |
| Cash and cash equivalents at beginning of period | 60.5 | 2.3 | 1.7 | — | 64.5 | |
| Cash and cash equivalents at end of period | \$266.5 | \$1.5 | \$4.3 | \$— | \$272.3 | |

Edgar Filing: HEALTHSOUTH CORP - Form 10-Q

HealthSouth Corporation and Subsidiaries
Notes to Condensed Consolidated Financial Statements
Condensed Consolidating Statement of Cash Flows

| | Nine Months Ended September 30, 2013 | | | | | |
|---|--|------------------------|---------------------------|---------------------|--------------------------|---|
| | HealthSouth Corporation (In Millions) | Guarantor Subsidiaries | Nonguarantor Subsidiaries | Eliminating Entries | HealthSouth Consolidated | |
| Net cash provided by operating activities | \$70.9 | \$215.6 | \$82.9 | \$— | \$369.4 | |
| Cash flows from investing activities: | | | | | | |
| Purchases of property and equipment | (5.2 |) (142.3 |) (19.3 |) — | (166.8 |) |
| Capitalized software costs | (4.8 |) (7.6 |) (3.2 |) — | (15.6 |) |
| Acquisition of business, net of cash acquired | — | (28.9 |) — | — | (28.9 |) |
| Proceeds from sale of restricted investments | — | — | 16.9 | — | 16.9 | |
| Proceeds from sale of Digital Hospital | 10.8 | — | — | — | 10.8 | |
| Purchase of restricted investments | — | — | (8.1 |) — | (8.1 |) |
| Other | (0.2 |) (1.0 |) (4.3 |) — | (5.5 |) |
| Net cash provided by (used in) investing activities | 0.6 | (179.8 |) (18.0 |) — | (197.2 |) |
| Cash flows from financing activities: | | | | | | |
| Principal borrowings on notes | — | — | 15.2 | — | 15.2 | |
| Borrowings on revolving credit facility | 147.0 | — | — | — | 147.0 | |
| Payments on revolving credit facility | (112.0 |) — | — | — | (112.0 |) |
| Repurchases of common stock, including fees and expenses | (234.1 |) — | — | — | (234.1 |) |
| Dividends paid on convertible perpetual preferred stock | (17.2 |) — | — | — | (17.2 |) |
| Distributions paid to noncontrolling interests of consolidated affiliates | — | — | (34.1 |) — | (34.1 |) |
| Other | 4.6 | (6.7 |) (2.7 |) — | (4.8 |) |
| Change in intercompany advances | 70.5 | (27.5 |) (43.0 |) — | — | |
| Net cash used in financing activities | (141.2 |) (34.2 |) (64.6 |) — | (240.0 |) |
| (Decrease) increase in cash and cash equivalents | (69.7 |) 1.6 | 0.3 | — | (67.8 |) |
| Cash and cash equivalents at beginning of period | 131.3 | 0.3 | 1.2 | — | 132.8 | |
| Cash and cash equivalents at end of period | \$61.6 | \$1.9 | \$1.5 | \$— | \$65.0 | |

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") relates to HealthSouth Corporation and its subsidiaries and should be read in conjunction with our condensed consolidated financial statements included under Part I, Item 1, Financial Statements (Unaudited), of this report and our audited consolidated financial statements for the year ended December 31, 2013 and Management's Discussion and Analysis of Financial Condition and Results of Operations which are included in our Annual Report on Form 10-K for the year ended December 31, 2013 (the "2013 Form 10-K").

This MD&A is designed to provide the reader with information that will assist in understanding our condensed consolidated financial statements, the changes in certain key items in those financial statements from period to period, and the primary factors that accounted for those changes, as well as how certain accounting principles affect our condensed consolidated financial statements. See "Cautionary Statements Regarding Forward-Looking Statements" on page i of this report for a description of important factors that could cause actual results to differ from expected results. See also Item 1A, Risk Factors, to the 2013 Form 10-K.

Executive Overview

Our Business

We are the nation's largest owner and operator of inpatient rehabilitation hospitals in terms of patients treated and discharged, revenues, and number of hospitals. While our national network of inpatient hospitals stretches across 28 states and Puerto Rico, we are concentrated in the eastern half of the United States and Texas. As of September 30, 2014, we operated 103 inpatient rehabilitation hospitals (including one hospital that operates as a joint venture which we account for using the equity method of accounting), 16 outpatient rehabilitation satellite clinics (operated by our hospitals), and 25 licensed, hospital-based home health agencies. In addition to HealthSouth hospitals, we manage three inpatient rehabilitation units through management contracts. For additional information about our business, see Item 1, Business, of the 2013 Form 10-K.

2014 Overview

Our 2014 strategy focuses on the following priorities:

- continuing to provide high-quality, cost-effective care to patients in our existing markets;
 - achieving organic growth at our existing hospitals;
 - expanding our services to more patients who require inpatient rehabilitative services by constructing and acquiring new hospitals in new markets;
 - continuing our shareholder value-enhancing strategies such as common stock dividends and repurchases of our common stock; and
- positioning the Company for continued success in the evolving healthcare delivery system. This preparation includes continuing the installation of our electronic clinical information system which allows for interfaces with all major acute care electronic medical record systems and health information exchanges, participating in bundling projects and Accountable Care Organizations ("ACOs"), and evaluating potential service line expansions via acquisitions. During the three months ended September 30, 2014, discharge growth of 3.8% coupled with a 2.7% increase in net patient revenue per discharge generated 6.6% growth in net patient revenue from our hospitals compared to the three months ended September 30, 2013. Discharge growth included a 1.9% increase in same-store discharges. During the nine months ended September 30, 2014, discharge growth of 3.1% coupled with a 3.0% increase in net patient revenue per discharge generated 6.2% growth in net patient revenue from our hospitals compared to the nine months ended September 30, 2013. Discharge growth included a 1.0% increase in same-store discharges. Our quality and outcome measures, as reported through the Uniform Data System for Medical Rehabilitation (the "UDS"), remained well above the average for hospitals included in the UDS database.

Our growth efforts in 2014 have included the continued development of the following de novo hospitals:

| Location | # of Beds | Actual / Expected Construction Start Date | Expected Operational Date |
|----------------------------|-----------|--|------------------------------|
| Altamonte Springs, Florida | 50 | Q4 2013 | Q4 2014 |
| Newnan, Georgia | 50 | Q4 2013 | Q4 2014 |
| Middletown, Delaware | 34 | Q4 2013 | Q4 2014 |
| Franklin, Tennessee* | 40 | Q4 2014 | Q4 2015 |
| Modesto, California | 50 | Q4 2014 | Q1 2016 |
| Murrieta, California** | 50 | Q3 2016 | Q4 2017 |

*In August 2014, the Tennessee Court of Appeals upheld the decision of the chancery court approving the award of our certificate of need, which decision allows us to begin building the approved inpatient rehabilitation hospital.

**In August 2014, we acquired land and began the design and permitting process to build an inpatient rehabilitation hospital.

In addition to the continued development of de novo hospitals, we continued our capacity expansions by adding six new beds to existing hospitals during the third quarter of 2014, and we expect to add 45 additional beds during the fourth quarter of 2014.

In April 2014, we signed an agreement with Mountain States Health Alliance to form a joint venture to own and operate a 26-bed, free-standing inpatient rehabilitation hospital in Johnson City, Tennessee. The formation of the joint venture is subject to customary closing conditions, including regulatory approvals. We expect to begin operating the joint venture in the fourth quarter of 2014.

In June 2014, we acquired an additional 30% equity interest from UMass Memorial Health Care, our joint venture partner in Fairlawn Rehabilitation Hospital (“Fairlawn”) in Worcester, Massachusetts. This transaction increased our ownership interest from 50% to 80% and resulted in a change in accounting for this hospital from the equity method of accounting to a consolidated entity. As a result of our consolidation of this hospital and the remeasurement of our previously held equity interest at fair value, we recorded a \$27.2 million gain as part of Other income during the nine months ended September 30, 2014. The transaction was funded using cash on hand. See Note 1, Basis of Presentation, and Note 2, Business Combinations, to the condensed consolidated financial statements included in Part 1, Item 1, Financial Statements (Unaudited), of this report for additional information.

In October 2014, we formed a joint venture with Memorial Health to obtain regulatory approvals to own and operate a 50-bed inpatient rehabilitation hospital to be known as the Rehabilitation Hospital of Savannah in Savannah, Georgia. Initially, the Rehabilitation Hospital of Savannah will operate in the current location of Memorial Health’s 50-bed Rehabilitation Institute on Memorial University Medical Center’s campus. The joint venture plans to build a new, 50-bed replacement inpatient rehabilitation hospital, which is expected to be completed in early 2016. The commencement of operations of the joint venture are subject to customary closing conditions, including certain regulatory approvals. We expect to begin operating the inpatient rehabilitation hospital at Memorial University Medical Center in the first half of 2015.

In September 2014, we issued an additional \$175 million of our 5.75% Senior Notes due 2024 at a price of 103.625% of the principal amount, which resulted in approximately \$182 million in net proceeds from the public offering. We also amended our existing credit agreement to, among other things, add a new \$150 million term loan facility to our existing \$600 million revolving credit facility and extend the maturity date to September 2019. In October 2014, we used the net proceeds from the additional offering of senior notes, a \$75 million draw under our term loan facility, and cash on hand to redeem the outstanding principal amount of our 7.25% Senior Notes due 2018. Pursuant to the terms of the 7.25% Senior Notes due 2018, this redemption was made at a price of 103.625%, which resulted in a total cash outlay of approximately \$281 million to retire the approximately \$271 million in principal. Additionally, in October 2014, we gave notice of the redemption of approximately \$25 million of the outstanding principal amount of our existing 7.75% Senior Notes due 2022. Pursuant to the terms of these senior notes, this optional redemption will represent 10% of the outstanding principal amount of the notes at a price of 103%, which will result in a total cash outlay of approximately \$26 million when the transaction closes in December 2014. See

Note 4, Long-term Debt, to the condensed consolidated financial statements included in Part I, Item 1, Financial Statements (Unaudited), of this report and the “Liquidity and Capital Resources” section of this Item.

We also continued our shareholder value-enhancing strategies by repurchasing 1.3 million shares of our common stock in the open market for \$43.1 million during the first and second quarters of 2014. In addition, we continued paying a quarterly cash dividend of \$0.18 per share on our common stock in the first three quarters of 2014. On July 17, 2014, our board of directors approved an increase in our quarterly dividend and declared a cash dividend of \$0.21 per share, paid on October 15, 2014 to stockholders of record on October 1, 2014. On October 21, 2014, our board of directors declared a cash dividend of \$0.21 per share, payable on January 15, 2015 to stockholders of record on January 2, 2015. See the “Liquidity and Capital Resources” section of this Item. In addition, we further strengthened our balance sheet by purchasing the real estate previously subject to a lease associated with our hospital in San Antonio, Texas.

Business Outlook

We believe our business outlook remains positive for two primary reasons. First, demographic trends, specifically the aging of the population, should increase long-term demand for inpatient rehabilitative services. While we treat patients of all ages, most of our patients are persons 65 and older (the average age of a HealthSouth patient is 72 years) and have conditions such as strokes, hip fractures, and a variety of debilitating neurological conditions that are generally nondiscretionary in nature and associated with the aging process. We believe the demand for inpatient rehabilitative healthcare services will continue to increase as the U.S. population ages and life expectancies increase. The number of Medicare enrollees is expected to grow approximately 3% per year for the foreseeable future.

Second, we are the industry leader in this growing sector. As the nation’s largest owner and operator of inpatient rehabilitation hospitals, we believe we differentiate ourselves from our competitors based on our broad platform of clinical expertise, the quality of our clinical outcomes, the sustainability of best practices, our financial strength, and the application of rehabilitation technology. We have invested considerable resources into clinical and management systems and protocols that have allowed us to consistently produce high-quality outcomes for our patients while continuing to contain cost growth. Our commitment to technology also includes the ongoing implementation of our rehabilitation-specific electronic clinical information system. We believe this system will improve patient care and safety, enhance staff recruitment and retention, and set the stage for connectivity with other providers and health information exchanges. Our hospitals also participate in The Joint Commission’s Disease-Specific Care Certification Program. Under this program, Joint Commission accredited organizations, like our hospitals, may seek certification for chronic diseases or conditions such as brain injury or stroke rehabilitation by complying with Joint Commission standards, effectively using evidence-based, clinical practice guidelines to manage and optimize patient care, and using an organized approach to performance measurement and evaluation of clinical outcomes. Obtaining such certifications demonstrates our commitment to excellence in providing disease-specific care. Currently, 96 of our hospitals hold one or more disease-specific certifications.

We believe these factors align with our strengths in, and focus on, inpatient rehabilitative care. Unlike many of our competitors that may offer inpatient rehabilitation as one of many secondary services, inpatient rehabilitation is our core business. In addition, we believe we can address the demand for inpatient rehabilitative services in markets where we currently do not have a presence by constructing or acquiring new hospitals.

Longer term, the nature and timing of the transformation of the current healthcare system to coordinated care delivery and payment models is uncertain and will likely remain so for some time. The development of new delivery and payment systems will almost certainly require significant time and resources. Many of the alternative approaches being explored may not work as intended. As outlined in Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations, “Key Challenges—Changes to Our Operating Environment Resulting from Healthcare Reform” of the 2013 Form 10-K, our goal is to position the Company in a prudent manner to be responsive to industry shifts.

Healthcare has always been a highly regulated industry, and we have cautioned our stakeholders that future Medicare payment rates could be at risk. While the Medicare reimbursement environment may be challenging, HealthSouth has a proven track record of adapting to and succeeding in a highly regulated environment, and we believe we are well positioned to continue to succeed and grow. Further, we believe the regulatory and reimbursement risks discussed

throughout this report may present us with opportunities to grow by acquiring or consolidating the operations of other inpatient rehabilitation providers in our highly fragmented industry. We have been disciplined in creating a capital structure that is flexible with no significant debt maturities prior to 2019. We have invested in our core business and created an infrastructure that enables us to provide high-quality care on a cost-effective basis. Our balance sheet remains strong. We have ample availability under our credit agreement, and we continue to generate strong cash flows from operations. Importantly, we have flexibility with how we choose to invest our cash and return value to shareholders including bed additions, de novos, acquisitions, purchases of leased properties, common stock dividends, repurchases of our common and preferred stock, and repayment of long-term debt. Specifically, on

February 14, 2014, our board of directors approved an increase in our existing common stock repurchase authorization from \$200 to \$250 million. As of September 30, 2014, approximately \$207 million remained under this authorization. In addition, on July 17, 2014, our board of directors approved an increase in our quarterly dividend and declared a cash dividend of \$0.21 per share, paid on October 15, 2014 to stockholders of record on October 1, 2014. See the “Liquidity and Capital Resources—Authorizations for Returning Capital to Stakeholders” section of this Item for additional information.

For these and other reasons, we believe we will be able to adapt to changes in reimbursement and sustain our business model. We also believe we will be in a position to take action should an attractive acquisition or consolidation opportunity arise.

Key Challenges

Currently, the healthcare industry is facing many well-publicized regulatory and reimbursement challenges. The industry is also facing uncertainty associated with the efforts, primarily arising from initiatives included in the 2010 Healthcare Reform Laws (as defined in Item 1, Business, “Regulatory and Reimbursement Challenges” of the 2013 Form 10-K) to identify and implement workable coordinated care delivery models. Successful healthcare providers are those who provide high-quality, cost-effective care and have the ability to adjust to changes in the regulatory and operating environments. We believe we have the necessary capabilities — scale, infrastructure, balance sheet, and management — to adapt to changes and continue to succeed in a highly regulated industry, and we have a proven track record of doing so.

As we continue to execute our business plan, the following are some of the challenges we face:

Operating in a Highly Regulated Industry. We are required to comply with extensive and complex laws and regulations at the federal, state, and local government levels. These rules and regulations have affected, or could in the future affect, our business activities by having an impact on the reimbursement we receive for services provided or the costs of compliance, mandating new documentation standards, requiring additional licensure or certification of our hospitals, regulating our relationships with physicians and other referral sources, regulating the use of our properties, and limiting our ability to enter new markets or add new beds to existing hospitals. Ensuring continuous compliance with extensive laws and regulations is an operating requirement for all healthcare providers.

We have invested, and will continue to invest, substantial time, effort, and expense in implementing and maintaining internal controls and procedures designed to ensure regulatory compliance, and we are committed to continued adherence to these guidelines. More specifically, because Medicare comprises a significant portion of our Net operating revenues, it is important for us to remain compliant with the laws and regulations governing the Medicare program and related matters including anti-kickback and anti-fraud requirements. If we were unable to remain compliant with these regulations, our financial position, results of operations, and cash flows could be materially, adversely impacted.

As discussed in Item 1, Business, “Sources of Revenues,” and Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations, “Executive Overview—Key Challenges,” of the 2013 Form 10-K, in connection with United States Centers for Medicare and Medicaid Services (“CMS”) approved and announced Recovery Audit Contractor (“RAC”) audits related to inpatient rehabilitation facilities (“IRFs”), we have received requests to review certain patient files for discharges occurring from 2010 to 2014. To date, the Medicare payments that are subject to these audit requests represent less than 1% of our Medicare patient discharges during those years, and not all of these patient file requests have resulted in payment denial determinations by the RACs. Because we have confidence in the medical judgment of both the referring and the admitting physicians who assess the treatment needs of their patients, we have appealed substantially all RAC denials arising from these audits.

The contracts awarded to RACs by CMS were set to expire in February 2014, but they have been extended and modified pending finalization of new contracts. In late February 2014, CMS announced it would pause the operations of the current RACs until new contracts are awarded, meaning that hospitals would not receive any new requests from RACs until that time. Legal challenges to the contract award process have delayed finalizing the new contracts longer than expected, and as a result, CMS modified the existing RAC contracts to allow some RAC reviews to be restarted on a limited basis. However, once the new contracts are in place, RACs will be able to audit claims for dates of service during the time period covered by the pause in RAC operations. We cannot predict when the legal challenges

to the new contracts will be resolved or when CMS will otherwise finalize the new RAC contracts. While we make provisions for these claims based on our historical experience and success rates in the claim adjudication process, we cannot provide assurance as to our future success in the resolution of

these and future disputes, nor can we predict or estimate the scope or number of denials that ultimately may be reviewed.

See also Item 1, Business, “Sources of Revenues” and “Regulation,” and Item 1A, Risk Factors, to the 2013 Form 10 K and Note 11, Contingencies and Other Commitments, “Governmental Inquiries and Investigations,” to the condensed consolidated financial statements included in Part I, Item 1, Financial Statements (Unaudited), of this report.

Changes to Our Operating Environment Resulting from Healthcare Reform. Our challenges related to healthcare reform are discussed in Item 1, Business, “Sources of Revenue,” Item 1A, Risk Factors, and Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations, “Executive Overview—Key Challenges,” to the 2013 Form 10 K.

Many provisions within the 2010 Healthcare Reform Laws have impacted, or could in the future impact, our business. Most notably for us are the reductions to our annual market basket updates, including productivity adjustments, and future payment reforms such as ACOs and bundled payments. Given the complexity and the number of changes in the 2010 Healthcare Reform Laws, we cannot predict their ultimate impact. In addition, the healthcare industry in general is facing uncertainty associated with the efforts, begun in earnest by initiatives included in the 2010 Healthcare Reform Laws, to identify and implement workable coordinated care delivery models. The ultimate nature and timing of the transformation of the healthcare delivery system is uncertain, and will likely remain so for some time. We will continue to evaluate these laws and position the Company for this industry shift. Based on our track record, we believe we can adapt to these regulatory and industry changes. Further, we have engaged, and will continue to engage, actively in discussions with key legislators and regulators to attempt to ensure any healthcare laws or regulations adopted or amended promote our goal of high-quality, cost-effective care.

On July 31, 2014, CMS released its notice of final rulemaking for fiscal year 2015 (the “2015 Rule”) for IRFs under the prospective payment system (“IRF-PPS”). The proposed rule will implement a net 2.2% market basket increase effective for discharges between October 1, 2014 and September 30, 2015, calculated as follows:

| | |
|-----------------------------|-----------------|
| Market basket update | 2.9% |
| Healthcare reform reduction | 20 basis points |
| Productivity adjustment | 50 basis points |

The final rule also includes other changes that impact our hospital-by-hospital base rate for Medicare reimbursement. Such changes include, but are not limited to, freezing the update to the IRF-PPS facility-level rural adjustment factor, low-income patient factor, and teaching status adjustment factor and updating the outlier fixed loss threshold. Based on our analysis which utilizes, among other things, the acuity of our patients over the 12-month period prior to the final rule’s release and incorporates other adjustments included in the final rule, we believe the 2015 Rule will result in a net increase to our Medicare payment rates of approximately 2.3% effective October 1, 2014, prior to the impact of sequestration.

Additionally, the final rule introduces, beginning on October 1, 2015, a new data collection requirement that will capture the minutes and mode (individual, group, concurrent, or co-treatment) of therapy by specialty. CMS plans to use this data to potentially support future rule making in this area. Further, the final rule includes revisions to the list of codes used by CMS to presumptively test compliance with the 60% Rule. The post-amputation codes that CMS plans to eliminate represented approximately 0.5% of our 2013 Medicare discharges. CMS also will require reporting of two new quality measures, beginning January 1, 2015, and will conduct validation audits to ensure the completeness and accuracy of the quality data submitted.

In October 2014, the President signed into law the Improving Medicare Post-Acute Care Transformation Act of 2014 (the “IMPACT Act”). The IMPACT Act was developed on a bi-partisan basis by the House Ways and Means and Senate Finance Committees and incorporated feedback from healthcare providers and provider organizations that responded to the Committees’ solicitation of post-acute payment reform ideas and proposals. It directs the United States Department of Health and Human Services (“HHS”), in consultation with healthcare stakeholders, to implement standardized data collection processes for post-acute quality and outcome measures. Although the IMPACT Act does not specifically call for the development of a new post-acute payment system, we believe this act will lay the foundation for possible future post-acute payment policies that would be based on patients’

medical conditions and other clinical factors rather than the setting where the care is provided. It will create additional data reporting requirements for our hospitals and home health agencies, and we expect to fully comply with these requirements. The precise details of these new reporting requirements, including timing and content, will be developed and implemented by CMS through the regulatory process that we expect will take place over the next several years. While we cannot quantify the potential financial effects of the IMPACT Act on HealthSouth, we believe any post-acute payment system that is data-driven and focuses on the needs and underlying medical conditions of post-acute patients ultimately will be a net positive for providers who offer high-quality, cost-effective care. However, it will likely take years for the related quality measures to be established, quality data to be gathered, standardized patient assessment data to be assembled and disseminated, and potential payment policies to be developed, tested, and promulgated. As the nation's largest owner and operator of inpatient rehabilitation hospitals, we look forward to working with HHS, the Medicare Payment Advisory Commission, and other healthcare stakeholders on these initiatives.

Maintaining Strong Volume Growth. Various factors may impact our ability to maintain our recent volume growth rates, including competition and increasing regulatory and administrative burdens. In any particular market, we may encounter competition from local or national entities with longer operating histories or other competitive advantages, such as acute care hospitals with their own rehabilitation units and other post-acute providers with relationships with referring acute care hospitals or physicians. Aggressive payment review practices by Medicare contractors, aggressive enforcement of regulatory policies by government agencies, and restrictive or burdensome rules, regulations or statutes governing admissions practices may lead us to not accept patients who would be appropriate for and would benefit from the services we provide. In addition, from time to time, we must get regulatory approval to add beds to our existing hospitals in states with certificate of need laws. This approval may be withheld or take longer than expected. In the case of new store volume growth, the addition of hospitals to our portfolio, whether de novo construction or the product of acquisitions or joint ventures, also may be difficult and take longer than expected.

Recruiting and Retaining High-Quality Personnel. See Item 1A, Risk Factors, to the 2013 Form 10 K for a discussion of competition for staffing, shortages of qualified personnel, and other factors that may increase our labor costs.

Recruiting and retaining qualified personnel for our hospitals remain a high priority for us. We attempt to maintain a comprehensive compensation and benefits package that allows us to remain competitive in this challenging staffing environment while remaining consistent with our goal of being a high-quality, cost-effective provider of inpatient rehabilitative services.

See also Item 1, Business, Item 1A, Risk Factors, and Item 7, Management's Discussion and Analysis of Financial Condition and Results of Operations, "Executive Overview—Key Challenges," to the 2013 Form 10 K.

These key challenges notwithstanding, we have a strong business model, a strong balance sheet, and a proven track record of achieving strong financial and operational results. We are attempting to position the Company to respond to changes in the healthcare delivery system and believe we will be ready to take advantage of opportunities that arise as the industry moves to this new stage. We believe we are postured to continue to grow, adapt to external events, and create value for our shareholders in 2014 and beyond.

Results of Operations

Payor Mix

During the three and nine months ended September 30, 2014 and 2013, we derived consolidated Net operating revenues from the following payor sources:

| | Three Months Ended September 30, | | Nine Months Ended September 30, | | |
|--|----------------------------------|---------|---------------------------------|---------|---|
| | 2014 | 2013 | 2014 | 2013 | |
| Medicare | 73.5 | % 74.1 | % 74.1 | % 74.5 | % |
| Medicaid | 2.2 | % 1.5 | % 1.8 | % 1.2 | % |
| Workers' compensation | 1.1 | % 1.3 | % 1.2 | % 1.3 | % |
| Managed care and other discount plans, including Medicare Advantage | 18.8 | % 18.7 | % 18.6 | % 18.5 | % |
| Other third-party payors | 1.8 | % 1.7 | % 1.7 | % 1.7 | % |
| Patients | 1.1 | % 1.1 | % 1.0 | % 1.1 | % |
| Other income | 1.5 | % 1.6 | % 1.6 | % 1.7 | % |
| Total | 100.0 | % 100.0 | % 100.0 | % 100.0 | % |

For additional information regarding our payors, see the "Sources of Revenues" section of Item 1, Business, of the 2013 Form 10-K.

Our Results

For the three and nine months ended September 30, 2014 and 2013, our consolidated results of operations were as follows:

| | Three Months Ended | | Percentage Change 2014 vs. 2013 | Nine Months Ended | | Percentage Change 2014 vs. 2013 | | |
|---|-----------------------|-----------------------|---------------------------------------|-----------------------|-----------------------|---------------------------------------|----------|---|
| | September 30, 2014 | September 30, 2013 | | September 30, 2014 | September 30, 2013 | | | |
| (In Millions, Except Percentage Change) | | | | | | | | |
| Net operating revenues | \$596.9 | \$564.0 | 5.8 | % | \$1,792.5 | \$1,701.1 | 5.4 | % |
| Less: Provision for doubtful accounts | (8.2) | (8.0) | 2.5 | % | (25.0) | (22.4) | 11.6 | % |
| Net operating revenues less provision for doubtful accounts | 588.7 | 556.0 | 5.9 | % | 1,767.5 | 1,678.7 | 5.3 | % |
| Operating expenses: | | | | | | | | |
| Salaries and benefits | 290.0 | 269.5 | 7.6 | % | 861.4 | 817.7 | 5.3 | % |
| Hospital-related expenses: | | | | | | | | |
| Other operating expenses | 89.4 | 82.2 | 8.8 | % | 260.2 | 241.3 | 7.8 | % |
| Occupancy costs | 10.3 | 11.7 | (12.0) | % | 31.1 | 35.8 | (13.1) | % |
| Supplies | 26.6 | 25.5 | 4.3 | % | 82.0 | 78.3 | 4.7 | % |
| General and administrative expenses | 27.5 | 28.8 | (4.5) | % | 88.4 | 88.5 | (0.1) | % |
| Depreciation and amortization | 27.4 | 24.3 | 12.8 | % | 80.2 | 69.5 | 15.4 | % |
| Government, class action, and related settlements | — | (21.3) | (100.0) | % | (0.8) | (23.3) | (96.6) | % |
| Professional fees—accounting, tax, and legal | 4.0 | 4.2 | (4.8) | % | 7.6 | 7.8 | (2.6) | % |
| Total operating expenses | 475.2 | 424.9 | 11.8 | % | 1,410.1 | 1,315.6 | 7.2 | % |
| Interest expense and amortization of debt discounts and fees | 27.8 | 25.3 | 9.9 | % | 83.5 | 73.9 | 13.0 | % |
| Other income | (0.2) | (0.6) | (66.7) | % | (30.1) | (3.2) | 840.6 | % |
| Equity in net income of nonconsolidated affiliates | (1.9) | (2.0) | (5.0) | % | (8.8) | (8.2) | 7.3 | % |
| Income from continuing operations before income tax expense (benefit) | 87.8 | 108.4 | (19.0) | % | 312.8 | 300.6 | 4.1 | % |
| Provision for income tax expense (benefit) | 22.1 | 35.2 | (37.2) | % | 91.4 | (17.8) | (613.5) | % |
| Income from continuing operations | 65.7 | 73.2 | (10.2) | % | 221.4 | 318.4 | (30.5) | % |
| (Loss) income from discontinued operations, net of tax | (0.9) | (0.9) | — | % | 2.8 | (1.2) | (333.3) | % |
| Net income | 64.8 | 72.3 | (10.4) | % | 224.2 | 317.2 | (29.3) | % |
| Less: Net income attributable to noncontrolling interests | (14.7) | (14.1) | 4.3 | % | (44.3) | (42.5) | 4.2 | % |
| Net income attributable to HealthSouth | \$50.1 | \$58.2 | (13.9) | % | \$179.9 | \$274.7 | (34.5) | % |

Provision for Doubtful Accounts and Operating Expenses as a % of Net Operating Revenues

| | Three Months Ended | | Nine Months Ended | | |
|---|--------------------|---------|-------------------|---------|----|
| | September 30, | | September 30, | | |
| | 2014 | 2013 | 2014 | 2013 | |
| Provision for doubtful accounts | 1.4 | % 1.4 | % 1.4 | % 1.3 | % |
| Operating expenses: | | | | | |
| Salaries and benefits | 48.6 | % 47.8 | % 48.1 | % 48.1 | % |
| Hospital-related expenses: | | | | | |
| Other operating expenses | 15.0 | % 14.6 | % 14.5 | % 14.2 | % |
| Occupancy costs | 1.7 | % 2.1 | % 1.7 | % 2.1 | % |
| Supplies | 4.5 | % 4.5 | % 4.6 | % 4.6 | % |
| General and administrative expenses | 4.6 | % 5.1 | % 4.9 | % 5.2 | % |
| Depreciation and amortization | 4.6 | % 4.3 | % 4.5 | % 4.1 | % |
| Government, class action, and related settlements | — | % (3.8) |)% — | % (1.4) |)% |
| Professional fees—accounting, tax, and legal | 0.7 | % 0.7 | % 0.4 | % 0.5 | % |
| Total operating expenses | 79.6 | % 75.3 | % 78.7 | % 77.3 | % |

Additional information regarding our operating results for the three and nine months ended September 30, 2014 and 2013 is as follows:

| | Three Months Ended | | Percentage Change | Nine Months Ended | | Percentage Change | | |
|--|--------------------|----------|-------------------|-------------------|-----------|-------------------|-------|----|
| | September 30, | | | September 30, | | | | |
| | 2014 | 2013 | 2014 vs. 2013 | 2014 | 2013 | 2014 vs. 2013 | | |
| (In Millions, Except Percentage Change) | | | | | | | | |
| Net patient revenue—inpatient | \$563.7 | \$528.8 | 6.6 | % | \$1,691.6 | \$1,593.3 | 6.2 | % |
| Net patient revenue—outpatient and other | 33.2 | 35.2 | (5.7) |)% | 100.9 | 107.8 | (6.4) |)% |
| Net operating revenues | \$596.9 | \$564.0 | 5.8 | % | \$1,792.5 | \$1,701.1 | 5.4 | % |
| (Actual Amounts) | | | | | | | | |
| Discharges | 33,541 | 32,307 | 3.8 | % | 100,050 | 97,082 | 3.1 | % |
| Net patient revenue per discharge | \$16,806 | \$16,368 | 2.7 | % | \$16,908 | \$16,412 | 3.0 | % |
| Outpatient visits | 183,450 | 202,479 | (9.4) |)% | 555,160 | 614,157 | (9.6) |)% |
| Average length of stay (days) | 13.2 | 13.3 | (0.8) |)% | 13.2 | 13.3 | (0.8) |)% |
| Occupancy % | 69.6 | % 69.0 | % 0.9 | % | 70.4 | % 69.9 | % 0.7 | % |
| # of licensed beds | 6,890 | 6,789 | 1.5 | % | 6,890 | 6,789 | 1.5 | % |
| Full-time equivalents* | 16,614 | 16,213 | 2.5 | % | 16,399 | 16,071 | 2.0 | % |
| Employees per occupied bed | 3.48 | 3.48 | — | % | 3.40 | 3.40 | — | % |

Excludes approximately 400 full-time equivalents who are considered part of corporate overhead with their salaries and benefits included in General and administrative expenses in our condensed

* consolidated statements of operations. Full-time equivalents included in the above table represent those who participate in or support the operations of our hospitals and exclude an estimate of full-time equivalents related to contract labor.

We actively manage the productive portion of our Salaries and benefits utilizing certain metrics, including employees per occupied bed, or “EPOB.” This metric is determined by dividing the number of full-time equivalents, including an estimate of full-time equivalents from the utilization of contract labor, by the number of occupied beds during each period. The number of occupied beds is determined by multiplying the number of licensed beds by our occupancy percentage.

In the discussion that follows, we use “same-store” comparisons to explain the changes in certain performance metrics and line items within our financial statements. We calculate same-store comparisons based on hospitals open throughout both the full current periods and prior periods presented. These comparisons include the financial results of

market consolidation

41

transactions in existing markets, as it is difficult to determine, with precision, the incremental impact of these transactions on our results of operations.

Net Operating Revenues

Net patient revenue from our hospitals was 6.6% higher for the three months ended September 30, 2014 than the three months ended September 30, 2013. This increase was attributable to a 3.8% increase in patient discharges and a 2.7% increase in net patient revenue per discharge. Discharge growth included a 1.9% increase in same-store discharges. Same-store discharges were negatively impacted by 40 basis points due to the closure of 40 skilled nursing facility beds in June 2014. Discharge growth from new stores resulted from the consolidation of Fairlawn effective June 1, 2014, as discussed in Note 2, Business Combinations, to the condensed consolidated financial statements included in Item 1, Financial Statements (Unaudited), of this report. The increase in net patient revenue per discharge resulted from Medicare and managed care price adjustments.

Net patient revenue from our hospitals was 6.2% higher for the nine months ended September 30, 2014 than the nine months ended September 30, 2013. This increase was attributable to a 3.1% increase in patient discharges and a 3.0% increase in net patient revenue per discharge. Discharge growth included a 1.0% increase in same-store discharges. Discharge growth for the year-to-date period of 2014 was impacted by the same factors as discussed above for the third quarter of 2014. In addition, winter storms negatively impacted same-store discharges in the first quarter of 2014 by approximately 100 basis points (approximately 60 basis points for the nine months ended September 30, 2014). Net patient revenue per discharge growth for the year-to-date period of 2014 resulted from price adjustments, higher average acuity for the patients we served, and contributions from hospitals that opened in the second quarter of 2013 and were undergoing Medicare certification. New hospitals are required to treat a minimum of 30 patients for zero revenue as part of the Medicare certification process. Net patient revenue per discharge was negatively impacted in the first quarter of 2014 by approximately \$9 million for sequestration, which anniversaried on April 1, 2014. Excluding the impact of sequestration, net patient revenue per discharge would have increased by 3.6% for the nine months ended September 30, 2014.

Decreased outpatient volumes in both periods of 2014 compared to the same periods of 2013 resulted from the closure of outpatient clinics and continued competition from physicians offering physical therapy services within their own offices. We had 16 and 21 outpatient rehabilitation satellite clinics as of September 30, 2014 and 2013, respectively. Outpatient and other revenues for the nine months ended September 30, 2013 included \$1.6 million of state provider tax refunds.

Provision for Doubtful Accounts

Pre-payment reviews focused on medical necessity criteria and conducted by Medicare Administrative Contractors ("MACs") have continued, and substantial delays in the adjudication process at the administrative law judge hearing level remain unabated. Accordingly, our outlook for our Provision for doubtful accounts remains at approximately 1.5% of Net operating revenues for 2014.

Salaries and Benefits

Salaries and benefits increased in the three and nine months ended September 30, 2014 compared to the same periods of 2013 primarily due to increased patient volumes, including an increase in the number of full-time equivalents as a result of our 2013 and 2014 development activities, and a 2.2% merit increase given to all eligible nonmanagement employees effective October 1, 2013.

The net impact of reductions in self-insurance reserves, as well as start-up costs associated with our de novo hospitals expected to open in the fourth quarter of 2014, resulted in an 80 basis points increase in Salaries and benefits as a percent of Net operating revenues in the three months ended September 30, 2014 compared to the same period of 2013. Excluding the impact of these two items, Salaries and benefits as a percent of Net operating revenues would have been flat in the third quarter of 2014 compared to the third quarter of 2013. Group medical and workers' compensation reserves were reduced by approximately \$3.0 million in the third quarter of 2014 as compared to approximately \$6.3 million in the third quarter of 2013, with both reductions due to favorable trends in claims.

Salaries and benefits as a percent of Net operating revenues was flat for the nine months ended September 30, 2014 compared to the same period of 2013 as increases resulting from the self-insurance reserves reductions discussed above and the negative impact of sequestration were offset by increased revenue and the maturation of three new

hospitals that opened in the second quarter of 2013. Without sequestration, Salaries and benefits as a percent of Net operating revenues would have decreased by 30 basis points in the nine months ended September 30, 2014 compared to the same period of 2013.

Salaries and benefits are expected to increase in the fourth quarter of 2014 due to a 2.25% merit increase provided to our nonmanagement employees effective October 1, 2014.

Hospital-related Expenses

Other Operating Expenses

Other operating expenses increased during the three and nine months ended September 30, 2014 compared to the same periods of 2013 primarily as a result of increased patient volumes and higher general and professional liability expenses. As a percent of Net operating revenues, Other operating expenses for the three and nine months ended September 30, 2014 increased when compared to the same periods of 2013 due primarily to higher general and professional liability expenses. The increase in Other operating expenses as a percent of Net operating revenues for the nine months ended September 30, 2014 compared to the same period of 2013 also included the effects of sequestration experienced in the first quarter of 2014.

Occupancy Costs

Occupancy costs decreased in total and as a percent of Net operating revenues in the 2014 periods presented compared to the same periods of 2013 due to our purchases of the real estate previously subject to operating leases at certain of our hospitals in the latter half of 2013 and first quarter of 2014.

Supplies

Supplies expense as a percent of Net operating revenues remained flat during the 2014 periods presented compared to the same periods of 2013 due primarily to our increasing revenue.

General and Administrative Expenses

General and administrative expenses decreased as a percent of Net operating revenues in the three months ended September 30, 2014 compared to the same period of 2013 due primarily to our increasing revenue and decreased expenses associated with stock-based compensation. General and administrative expenses decreased as a percent of Net operating revenues in the nine months ended September 30, 2014 compared to the same period of 2013 due primarily to our increasing revenue and the deferral and amortization of the gain associated with the 2013 Digital Hospital transaction discussed in Note 5, Property and Equipment, to the consolidated financial statements accompanying the 2013 Form 10-K.

Depreciation and Amortization

Depreciation and amortization increased during the three and nine months ended September 30, 2014 compared to the same periods of 2013 due to our increased capital expenditures throughout 2013 and 2014.

Government, Class Action, and Related Settlements

The gain included in Government, class action, and related settlements for the three and nine months ended September 30, 2013 resulted from a noncash reduction in the estimated liability associated with the apportionment obligation to the plaintiffs in the January 2007 comprehensive settlement of the consolidated securities action, the collection of final judgments against former officers, and the recovery of assets from former officers, as discussed in Note 11, Contingencies and Other Commitments, to the condensed consolidated financial statements included in Part I, Item 1, Financial Statements (Unaudited), of this report and Note 18, Contingencies and Other Commitments, to the consolidated financial statements accompanying the 2013 Form 10-K.

Professional Fees—Accounting, Tax, and Legal

Professional fees—accounting, tax, and legal for the three and nine months ended September 30, 2014 and 2013 related primarily to legal and consulting fees for continued litigation and support matters discussed in Note 11, Contingencies and Other Commitments, to the condensed consolidated financial statements included in Part I, Item 1, Financial Statements (Unaudited), of this report and Note 18, Contingencies and Other Commitments, to the consolidated financial statements accompanying the 2013 Form 10-K.

Interest Expense and Amortization of Debt Discounts and Fees

The increase in Interest expense and amortization of debt discounts and fees during the three and nine months ended September 30, 2014 compared to the same periods of 2013 resulted from an increase in our average borrowings outstanding

offset by a decrease in our average cash interest rate. Average borrowings outstanding increased in 2014 over 2013 primarily as a result of our issuance of \$320 million in aggregate principal amount of newly issued 2.00% Convertible Senior Subordinated Notes due 2043 for 257,110 shares of our outstanding preferred stock in November 2013. Our average cash interest rate approximated 6.5% during 2014 and 7.4% and 7.2%, respectively, during the three and nine months ended September 30, 2013.

See also Note 4, Long-term Debt, to the condensed consolidated financial statements included in Part I, Item 1, Financial Statements (Unaudited), of this report for information regarding debt transactions in September and October 2014 that will favorably impact interest expense going forward.

Other Income

Other income for the nine months ended September 30, 2014 included a \$27.2 million gain related to the acquisition of an additional 30% equity interest in Fairlawn. See Note 2, Business Combinations, to the condensed consolidated financial statements included in Part I, Item 1, Financial Statements (Unaudited), of this report.

Equity in Net Income of Nonconsolidated Affiliates

Equity in net income of nonconsolidated affiliates for the nine months ended September 30, 2014 included an approximate \$1 million gain from the sale of the underlying assets of an equity investment.

Income from Continuing Operations Before Income Tax Expense (Benefit)

Our pre-tax income from continuing operations for the three and nine months ended September 30, 2014 included the \$27.2 million gain related to the acquisition of an additional equity interest in Fairlawn. Excluding this gain, the increase in our pre-tax income in the periods presented resulted from increased Net operating revenues.

Provision for Income Tax Expense (Benefit)

Due to our federal and state net operating loss carryforwards (“NOLs”), we currently estimate our cash income tax expense to be approximately \$12 million to \$17 million, net of refunds, for 2014. These payments are expected to result from state income tax expense of subsidiaries which have separate state filing requirements, alternative minimum taxes, and federal income taxes for subsidiaries not included in our federal consolidated income tax return. For the three months ended September 30, 2014 and 2013, current income tax expense was \$3.2 million and \$2.5 million, respectively. For the nine months ended September 30, 2014 and 2013, current income tax expense was \$9.8 million and \$3.0 million, respectively.

Our Provision for income tax expense of \$22.1 million and \$91.4 million for the three and nine months ended September 30, 2014, respectively, primarily resulted from the application of our estimated effective blended federal and state income tax rates, which were reduced as a result of the nontaxable gain related to our acquisition of an additional 30% equity interest in Fairlawn and our election to claim certain tax credits. As a result of the Fairlawn transaction discussed in Note 2, Business Combinations, to the condensed consolidated financial statements included in Part I, Item 1, Financial Statements (Unaudited), of this report, we released the deferred tax liability associated with the outside tax basis of our investment in Fairlawn because we now possess sufficient ownership to allow for the historical outside tax basis difference to be resolved through a tax-free transaction in the future.

Our Provision for income tax expense of \$35.2 million for the three months ended September 30, 2013, primarily resulted from the application of our estimated effective blended federal and state income tax rate offset by a decrease in our valuation allowance due to changes in certain state tax laws and provision to return adjustments made as a result of the filing of our federal income tax return for 2012. Our Provision for income tax benefit of \$17.8 million for the nine months ended September 30, 2013 primarily resulted from the IRS settlement discussed in Note 9, Income Taxes, to the condensed consolidated financial statements included in Part I, Item 1, Financial Statements (Unaudited), of this report. It also included an approximate \$4 million decrease in our valuation allowance related primarily to our capital loss carryforwards and changes in certain state tax laws. During the second quarter of 2013, we determined a valuation allowance related to our capital loss carryforwards was no longer required as sufficient positive evidence existed to substantiate their utilization. This evidence included our partial utilization of these assets as a result of realizing capital gains in the current year and the identification of sufficient taxable capital gain income within the available capital loss carryforward period.

In certain state jurisdictions, we do not expect to generate sufficient income to use all of our available NOLs prior to their expiration. This determination is based on our evaluation of all available evidence in these jurisdictions including

results of operations during the preceding three years, our forecast of future earnings, and prudent tax planning strategies. It is possible we may be required to increase or decrease our valuation allowance at some future time if our forecast of future earnings varies

from actual results on a consolidated basis or in the applicable state tax jurisdiction, or if the timing of future tax deductions differs from our expectations.

We recognize the financial statement effects of uncertain tax positions when it is more likely than not, based on the technical merits, a position will be sustained upon examination by and resolution with the taxing authorities. Total remaining gross unrecognized tax benefits were \$0.4 million and \$1.1 million as of September 30, 2014 and December 31, 2013, respectively.

See Note 9, Income Taxes, to the condensed consolidated financial statements included in Part I, Item 1, Financial Statements (Unaudited), of this report and Note 16, Income Taxes, to the consolidated financial statements accompanying the 2013 Form 10-K.

Net Income Attributable to Noncontrolling Interests

Net income attributable to noncontrolling interests represents the share of net income or loss allocated to members or partners in our consolidated affiliates. Fluctuations in these amounts are primarily driven by the financial performance of the applicable hospital population each period.

Results of Discontinued Operations

In connection with the 2007 sale of our surgery centers division (now known as Surgical Care Affiliates, or "SCA") to ASC Acquisition LLC, an affiliate of TPG Partners V, L.P. ("TPG"), a private investment partnership, we received an option, subject to terms and conditions set forth below, to purchase up to a 5% equity interest in SCA. The price of the option is equal to the original issuance price of the units subscribed for by TPG and certain other co-investors in connection with the acquisition plus a 15% premium, compounded annually. The option has a term of ten years and is exercisable upon certain liquidity events, including a public offering of SCA's shares of common stock that results in 30% or more of SCA's common stock being listed or traded on a national securities exchange. On November 4, 2013, SCA announced the closing of its initial public offering, which was not a qualifying liquidity event.

During the second quarter of 2014, we entered into an amendment to the option agreement that requires us to settle the option net of our exercise price. The addition of this new feature resulted in the option becoming a derivative that must be recorded as an asset or liability on our condensed consolidated balance sheet and marked to market each period. As of September 30, 2014, the fair value of this option was \$5.1 million and is included in Other long-term assets in our condensed consolidated balance sheet. Income from discontinued operations, net of tax for the three and nine months ended September 30, 2014 included a \$1.6 million loss and \$5.1 million net gain, respectively, resulting from the initial recording of this option as a derivative and its fair value adjustments during the 2014 periods presented. If the option becomes exercisable, we believe it will have a strike price below the price of the asset being purchased.

For additional information regarding discontinued operations, see Note 8, Assets and Liabilities in and Results of Discontinued Operations, to the condensed consolidated financial statements included in Part 1, Item 1, Financial Statements (Unaudited), of this report, and Note 15, Assets and Liabilities in and Results of Discontinued Operations, to the consolidated financial statements accompanying the 2013 Form 10-K.

Liquidity and Capital Resources

Our primary sources of liquidity are cash on hand, cash flows from operations, and borrowings under our credit agreement.

The objectives of our capital structure strategy are to ensure we maintain adequate liquidity and flexibility. Pursuing and achieving those objectives allows us to support the execution of our operating and strategic plans and weather temporary disruptions in the capital markets and general business environment. Maintaining adequate liquidity is a function of our unrestricted Cash and cash equivalents and our available borrowing capacity. Maintaining flexibility in our capital structure is a function of, among other things, the amount of debt maturities in any given year, the options for debt prepayments without onerous penalties, and limiting restrictive terms and maintenance covenants in our debt agreements.

Consistent with these objectives, in September 2014, we issued an additional \$175 million of our 5.75% Senior Notes due 2024 at a price of 103.625% of the principal amount. We also amended our existing credit agreement to, among other things:

-

add a new \$150 million term loan facility (under which amounts may be drawn on or before March 31, 2015) in addition to our existing \$600 million revolving credit facility;

permit additional restricted payments so long as the senior secured leverage ratio remains less than or equal to 1.75x (previously 1.50x);

increase the amount of permitted capital expenditures in a given year from \$250 million to \$300 million; and set the maturity date for both the revolving credit and term loan facilities to September 2019, which represents a one-year extension for our existing revolving credit facility.

In October 2014, we used the net proceeds from the additional offering of senior notes, a \$75 million draw under our term loan facility, and cash on hand to redeem the outstanding principal amount of our 7.25% Senior Notes due 2018. Pursuant to the terms of the 7.25% Senior Notes due 2018, this redemption was made at a price of 103.625%, which resulted in a total cash outlay of approximately \$281 million to retire the approximately \$271 million in principal. Additionally, in October 2014, we gave notice of the redemption of approximately \$25 million of the outstanding principal amount of our existing 7.75% Senior Notes due 2022. Pursuant to the terms of these senior notes, this optional redemption will represent 10% of the outstanding principal amount of the notes at a price of 103%, which will result in a total cash outlay of approximately \$26 million when the transaction closes in December 2014. As a result of these redemptions, we expect to record an approximate \$13 million loss on early extinguishment of debt in the fourth quarter of 2014. See Note 4, Long-term Debt, to the condensed consolidated financial statements included in Part I, Item 1, Financial Statements (Unaudited), of this report.

We have been disciplined in creating a capital structure that is flexible with no significant debt maturities prior to 2019. Our balance sheet remains strong, and we have ample availability under our credit agreement. We continue to generate strong cash flows from operations, and we have significant flexibility with how we choose to invest our cash and return capital to shareholders.

Current Liquidity

As of September 30, 2014, we had \$272.3 million in Cash and cash equivalents. This amount included approximately \$182 million of proceeds from the public offering of an additional \$175 million of principal amount of our 5.75% Senior Notes due 2024 in September 2014. As discussed above, in October 2014, we used the net proceeds along with other funding sources to redeem the outstanding principal amount of our 7.25% Senior Notes due 2018. See Note 4, Long-term Debt, to the condensed consolidated financial statements included in Part I, Item 1, Financial Statements (Unaudited), of this report.

Cash and cash equivalents as of September 30, 2014 excluded \$54.1 million in restricted cash and \$50.2 million of restricted marketable securities (\$4.3 million included in Other current assets and \$45.9 million included in Other long-term assets in our condensed consolidated balance sheet as of September 30, 2014). Our restricted assets pertain primarily to obligations associated with our captive insurance company, as well as obligations we have under agreements with joint venture partners. See Note 3, Cash and Marketable Securities, to the consolidated financial statements accompanying the 2013 Form 10-K.

In addition to Cash and cash equivalents, as of September 30, 2014, we had approximately \$718 million available to us under our credit agreement — \$568 million under our revolving credit facility and \$150 million under our term loan facility. Our credit agreement governs the substantial majority of our senior secured borrowing capacity and contains a leverage ratio and an interest coverage ratio as financial covenants. Our leverage ratio is defined in our credit agreement as the ratio of consolidated total debt (less up to \$75 million of cash on hand) to Adjusted EBITDA for the trailing four quarters. Our interest coverage ratio is defined in our credit agreement as the ratio of Adjusted EBITDA to consolidated interest expense, excluding the amortization of financing fees, for the trailing four quarters. As of September 30, 2014, the maximum leverage ratio requirement per our credit agreement was 4.5x and the minimum interest coverage ratio requirement was 2.75x, and we were in compliance with these covenants. Based on Adjusted EBITDA for the trailing four quarters and the interest rate in effect under our credit agreement during the three-month period ended September 30, 2014, if we had drawn on the first day and maintained the maximum amount of outstanding draws under our revolving credit facility for that entire period, we would still be in compliance with the maximum leverage ratio and minimum interest coverage ratio requirements.

We do not face near-term refinancing risk, as the amounts outstanding under our credit agreement do not mature until 2019, and our bonds, after the redemption of the 7.25% Senior Notes due 2018 in October 2014 as described above, all mature in 2020 and beyond. See the “Contractual Obligations” section below for information related to our

contractual obligations as of September 30, 2014.

We anticipate we will continue to generate strong cash flows from operations that, together with availability under our credit agreement, will allow us to invest in growth opportunities and continue to improve our existing core business.

We also will continue to consider additional shareholder value-enhancing strategies such as repurchases of our common and preferred

stock and common stock dividends, including the potential growth of the quarterly cash dividend on our common stock, recognizing that these actions may increase our leverage ratio. See also the “Authorizations for Returning Capital to Stakeholders” section of this Item.

See Item 1A, Risk Factors, of the 2013 Form 10-K for a discussion of risks and uncertainties facing us.

Sources and Uses of Cash

The following table shows the cash flows provided by or used in operating, investing, and financing activities for the nine months ended September 30, 2014 and 2013 (in millions):

| | Nine Months Ended September 30, | |
|--|---------------------------------|----------|
| | 2014 | 2013 |
| Net cash provided by operating activities | \$374.7 | \$369.4 |
| Net cash used in investing activities | (162.3 |) (197.2 |
| Net cash used in financing activities | (4.6 |) (240.0 |
| Increase (decrease) in cash and cash equivalents | \$207.8 | \$(67.8) |

Operating activities. Net cash provided by operating activities increased during the nine months ended September 30, 2014 compared to the same period of 2013 due primarily to increased Net operating revenues. Net cash provided by operating activities for the nine months ended September 30, 2014 included the impact of increased working capital resulting from the growth in accounts receivable related to the resumption of medical claims denials by a MAC.

Investing activities. The decrease in Net cash used in investing activities during the nine months ended September 30, 2014 compared to the same period of 2013 primarily resulted from the timing of capital expenditures. Net cash used in investing activities included \$15.9 million and \$28.9 million related to the acquisition of Fairlawn and Walton Rehabilitation Hospital, respectively, during the nine months ended September 30, 2014 and 2013, respectively. See the “Contractual Obligations” section below for a discussion of our expected capital expenditures during 2014.

Financing activities. The decrease in Net cash used in financing activities during the nine months ended September 30, 2014 compared to the same period of 2013 primarily resulted from repurchases of our common stock as part of the tender offer completed in the first quarter of 2013. We repurchased 9.1 million shares of our common stock for \$232.5 million during the first quarter of 2013. During the nine months ended September 30, 2014, we repurchased 1.3 million shares of our common stock in the open market for \$43.1 million. Net cash used in financing activities for the nine months ended September 30, 2014 also included \$175.0 million from the additional offering of our 5.75% Senior Notes due 2024 in September 2014, as discussed above.

Contractual Obligations

Our consolidated contractual obligations as of September 30, 2014 are as follows (in millions):

| | Total | October 1 through December 31, 2014 | 2015 - 2016 | 2017 - 2018 | 2019 and thereafter |
|--|-----------|--|-------------|-------------|------------------------|
| Long-term debt obligations: | | | | | |
| Long-term debt, excluding revolving credit facility and capital lease obligations ^(a) | \$1,565.6 | \$272.9 | \$4.9 | \$2.1 | \$1,285.7 |
| Revolving credit facility | — | — | — | — | — |
| Interest on long-term debt ^(b) | 755.5 | 19.7 | 157.0 | 156.6 | 422.2 |
| Capital lease obligations ^(c) | 166.3 | 3.0 | 27.1 | 27.0 | 109.2 |
| Operating lease obligations ^{(d)(e)} | 237.7 | 10.0 | 72.0 | 52.9 | 102.8 |
| Purchase obligations ^{(e)(f)} | 102.9 | 6.8 | 49.5 | 20.8 | 25.8 |
| Other long-term liabilities ^{(g)(h)} | 3.8 | 0.1 | 0.4 | 0.4 | 2.9 |
| Total | \$2,831.8 | \$312.5 | \$310.9 | \$259.8 | \$1,948.6 |

Included in long-term debt are amounts owed on our bonds payable and other notes payable. These borrowings are further explained in Note 4, Long-term Debt, to the condensed consolidated financial statements included in Part I, Item 1, Financial Statements (Unaudited), of this report and Note 8, Long-term Debt, to the consolidated financial statements accompanying the 2013 Form 10-K. See also Note 4, Long-term Debt, to the condensed consolidated financial statements included in Part I, Item 1, Financial Statements (Unaudited), of this report for a discussion of our redemption of approximately \$271 million in principal of our 7.25% Senior Notes due 2018 in October 2014, as well as our intent to redeem approximately \$25 million in principal of our 7.75% Senior Notes due 2022 in December 2014.

Interest on our fixed rate debt is presented using the stated interest rate. Interest expense on our variable rate debt is estimated using the rate in effect as of September 30, 2014. Interest pertaining to our credit agreement and bonds is included to their respective ultimate maturity dates. Interest related to capital lease obligations is excluded from this line. Future minimum payments, which are accounted for as interest, related to sale/leaseback transactions involving real estate accounted for as financings are included in this line (see Note 5, Property and Equipment, and Note 8, Long-term Debt, to the consolidated financial statements accompanying the 2013 Form 10-K). Amounts exclude amortization of debt discounts, amortization of loan fees, or fees for lines of credit that would be included in interest expense in our consolidated statements of operations.

Amounts include interest portion of future minimum capital lease payments.

We lease approximately 16% of our hospitals as well as other property and equipment under operating leases in the normal course of business. Some of our hospital leases contain escalation clauses based on changes in the Consumer Price Index while others have fixed escalation terms. The minimum lease payments do not include contingent rental expense. Some lease agreements provide us with the option to renew the lease or purchase the leased property. Our future operating lease obligations would change if we exercised these renewal options and if we entered into additional operating lease agreements. For more information, see Note 5, Property and Equipment, to the consolidated financial statements accompanying the 2013 Form 10-K.

Future operating lease obligations and purchase obligations are not recognized in our condensed consolidated balance sheet.

Purchase obligations include agreements to purchase goods or services that are enforceable and legally binding on HealthSouth and that specify all significant terms, including: fixed or minimum quantities to be purchased; fixed, minimum, or variable price provisions; and the approximate timing of the transaction. Purchase obligations exclude agreements that are cancelable without penalty. Our purchase obligations primarily relate to software licensing and support.

Because their future cash outflows are uncertain, the following noncurrent liabilities are excluded from the table above: general liability, professional liability, and workers' compensation risks, noncurrent amounts related to third-party billing audits, and deferred income taxes. Also, at September 30, 2014, we had \$0.4 million of total (g) gross unrecognized tax benefits. For more information, see Note 9, Self-Insured Risks, Note 16, Income Taxes, and Note 18, Contingencies and Other Commitments, to the consolidated financial statements accompanying the 2013 Form 10-K and Note 9, Income Taxes, to the condensed consolidated financial statements included in Part I, Item 1, Financial Statements (Unaudited), of this report.

(h) The table above does not include Redeemable noncontrolling interests of \$12.2 million because of the uncertainty surrounding the timing and amounts of any related cash outflows.

Our capital expenditures include costs associated with our hospital refresh program, de novo projects, capacity expansions, technology initiatives, and building and equipment upgrades and purchases. During the nine months ended September 30, 2014, we made capital expenditures of approximately \$147 million for property and equipment and capitalized software. These expenditures included \$17.3 million for the purchase of the real estate previously subject to a lease associated with our hospital in San Antonio, Texas and approximately \$12 million of hospital and technology equipment that was received in 2013 but not paid for until 2014. These expenditures through the first nine months of 2014 are exclusive of \$15.9 million in net cash related to the increase in ownership of Fairlawn, as discussed in Note 2, Business Combinations, to the condensed consolidated financial statements included in Item 1, Financial Statements (Unaudited), of this report. During 2014, we expect to spend approximately \$180 million to \$225 million for capital expenditures. This estimated range for capital expenditures is exclusive of acquisitions. Approximately \$85 million to \$95 million of this budgeted amount is considered nondiscretionary expenditures, which we may refer to in other filings as "maintenance" expenditures. Actual amounts spent will be dependent upon the timing of construction projects.

Authorizations for Returning Capital to Stakeholders

On October 15, 2013, we paid the first cash dividend, \$0.18 per share, on our common stock, and we paid the same per share dividend quarterly through July 15, 2014. On July 17, 2014, our board of directors approved an increase in our quarterly dividend to \$0.21 per share, which was paid on October 15, 2014 to stockholders of record on October 1, 2014. On October 21, 2014, our board of directors declared a cash dividend of \$0.21 per share, payable on January 15, 2015 to stockholders of record on January 2, 2015. We expect quarterly dividends to be paid in January, April, July, and October. However, the actual declaration of any future cash dividends, and the setting of record and payment dates as well as the per share amounts, will be at the discretion of our board of directors after consideration of various factors, including our capital position and alternative uses of funds. Cash dividends are expected to be funded using cash flows from operations, cash on hand, and availability under our credit agreement.

The payment of cash dividends on our common stock triggers antidilution adjustments, except in instances when such adjustments are deemed de minimis, under our convertible notes and our convertible perpetual preferred stock. See Note 8, Long-term Debt, Note 10, Convertible Perpetual Preferred Stock, and Note 17, Earnings per Common Share, to the consolidated financial statements accompanying the 2013 Form 10-K and Note 10, Earnings per Common Share, to the condensed consolidated financial statements included in Item 1, Financial Statements (Unaudited), of this report.

On February 14, 2014, our board of directors approved an increase in our existing common stock repurchase authorization from \$200 million to \$250 million. The repurchase authorization does not require the repurchase of a specific number of shares, has an indefinite term, and is subject to termination at any time by our board of directors. Subject to certain terms and conditions, including a maximum price per share and compliance with federal and state securities and other laws, the repurchases may be made from time to time in open market transactions, privately negotiated transactions, or other transactions, including trades under a plan established in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. During the nine months ended September 30, 2014, we repurchased 1.3 million shares of our common stock in the open market for \$43.1 million under this repurchase authorization using cash on hand. Future repurchases under this authorization generally are expected to be funded using a combination of cash on hand and availability under our \$600 million revolving credit facility.

See also Note 4, Long-term Debt, to the condensed consolidated financial statements included in Part I, Item 1, Financial Statements (Unaudited), of this report for a discussion of our redemption of approximately \$271 million in principal of our 7.25% Senior Notes due 2018 in October 2014, as well as our intent to redeem approximately \$25 million in principal of our 7.75% Senior Notes due 2022 in December 2014.

Adjusted EBITDA

Management believes Adjusted EBITDA as defined in our credit agreement is a measure of our ability to service our debt and our ability to make capital expenditures. We reconcile Adjusted EBITDA to Net income and to Net cash provided by operating activities.

We use Adjusted EBITDA on a consolidated basis as a liquidity measure. We believe this financial measure on a consolidated basis is important in analyzing our liquidity because it is the key component of certain material covenants contained within our credit agreement, which is discussed in more detail in Note 8, Long-term Debt, to the consolidated financial statements accompanying the 2013 Form 10-K. These covenants are material terms of the credit agreement. Noncompliance with these financial covenants under our credit agreement—our interest coverage ratio and our leverage ratio—could result in our lenders requiring us to immediately repay all amounts borrowed. If we anticipated a potential covenant violation, we would seek relief from our lenders, which would have some cost to us, and such relief might not be on terms favorable to those in our existing credit agreement. In addition, if we cannot satisfy these financial covenants, we would be prohibited under our credit agreement from engaging in certain activities, such as incurring additional indebtedness, paying common stock dividends, making certain payments, and acquiring and disposing of assets. Consequently, Adjusted EBITDA is critical to our assessment of our liquidity.

In general terms, the credit agreement definition of Adjusted EBITDA, referred to as “Adjusted Consolidated EBITDA” there, allows us to add back to consolidated Net income interest expense, income taxes, and depreciation and amortization and then add back to consolidated Net income (1) all unusual or nonrecurring items reducing consolidated Net income (of which only up to \$10 million in a year may be cash expenditures), (2) any losses from discontinued operations and closed locations, (3) costs and expenses, including legal fees and expert witness fees, incurred with respect to litigation associated with stockholder derivative litigation, including the matters related to Ernst & Young, LLP and Richard Scrushy discussed in Note 18, Contingencies and Other Commitments, to the consolidated financial statements accompanying the 2013 Form 10-K and Note 11, Contingencies and Other Commitments, to the condensed consolidated financial statements included in Part I, Item 1, Financial Statements (Unaudited), of this report, and (4) share-based compensation expense. We also subtract from consolidated Net income all unusual or nonrecurring items to the extent increasing consolidated Net income.

Under the credit agreement, the Adjusted EBITDA calculation does not include net income attributable to noncontrolling interests and includes (1) gain or loss on disposal of assets, (2) professional fees unrelated to the stockholder derivative litigation, and (3) unusual or nonrecurring cash expenditures in excess of \$10 million. These items may not be indicative of our ongoing performance, so the Adjusted EBITDA calculation presented here includes adjustments for them.

Adjusted EBITDA is not a measure of financial performance under generally accepted accounting principles in the United States of America, and the items excluded from Adjusted EBITDA are significant components in understanding and assessing financial performance. Therefore, Adjusted EBITDA should not be considered a substitute for Net income or cash flows from operating, investing, or financing activities. Because Adjusted EBITDA is not a measurement determined in accordance with GAAP and is thus susceptible to varying calculations, Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures of other companies. Revenues and expenses are measured in accordance with the policies and procedures described in Note 1, Summary of Significant Accounting Policies, to the consolidated financial statements accompanying the 2013 Form 10-K.

Our Adjusted EBITDA for the three and nine months ended September 30, 2014 and 2013 was as follows (in millions):

Reconciliation of Net Income to Adjusted EBITDA

| | Three Months Ended | | Nine Months Ended | |
|---|--------------------|---------|-------------------|---------|
| | September 30, | | September 30, | |
| | 2014 | 2013 | 2014 | 2013 |
| Net income | \$64.8 | \$72.3 | \$224.2 | \$317.2 |
| Loss (income) from discontinued operations, net of tax, attributable to HealthSouth | 0.9 | 0.9 | (2.8) | 1.2 |
| Provision for income tax expense (benefit) | 22.1 | 35.2 | 91.4 | (17.8) |
| Interest expense and amortization of debt discounts and fees | 27.8 | 25.3 | 83.5 | 73.9 |
| Professional fees—accounting, tax, and legal | 4.0 | 4.2 | 7.6 | 7.8 |
| Government, class action, and related settlements | — | (21.3) | (0.8) | (23.3) |
| Net noncash loss on disposal or impairment of assets | 2.7 | 2.5 | 5.7 | 4.3 |
| Depreciation and amortization | 27.4 | 24.3 | 80.2 | 69.5 |
| Stock-based compensation expense | 5.0 | 6.2 | 19.3 | 19.0 |
| Net income attributable to noncontrolling interests | (14.7) | (14.1) | (44.3) | (42.5) |
| Gain on consolidation of Fairlawn Rehabilitation Hospital | — | — | (27.2) | — |
| Adjusted EBITDA | \$140.0 | \$135.5 | \$436.8 | \$409.3 |

Reconciliation of Net Cash Provided by Operating Activities to Adjusted EBITDA

| | Nine Months Ended September 30, | |
|--|---------------------------------|---------|
| | 2014 | 2013 |
| Net cash provided by operating activities | \$374.7 | \$369.4 |
| Provision for doubtful accounts | (25.0) | (22.4) |
| Professional fees—accounting, tax, and legal | 7.6 | 7.8 |
| Interest expense and amortization of debt discounts and fees | 83.5 | 73.9 |
| Equity in net income of nonconsolidated affiliates | 8.8 | 8.2 |
| Net income attributable to noncontrolling interests in continuing operations | (44.3) | (42.5) |
| Amortization of debt discounts and fees | (9.5) | (3.0) |
| Distributions from nonconsolidated affiliates | (9.4) | (9.6) |
| Current portion of income tax expense | 9.8 | 3.0 |
| Change in assets and liabilities | 43.7 | 21.8 |
| Premium received on bond issuance | (6.3) | — |
| Net cash used in operating activities of discontinued operations | 1.0 | 1.4 |
| Other | 2.2 | 1.3 |
| Adjusted EBITDA | \$436.8 | \$409.3 |

Growth in Adjusted EBITDA for the 2014 periods presented compared to the same periods of 2013 resulted primarily from continued revenue growth. Adjusted EBITDA for the three and nine months ended September 30, 2014 included a \$2.0 million and a \$3.3 million, respectively, benefit from the increase in ownership and consolidation of Fairlawn. These benefits were offset by the net effect of self-insurance reserve adjustments and start-up costs for hospitals opening in the fourth quarter of 2014, as discussed in the “Results of Operations” section of this Item. Adjusted EBITDA for the nine months ended September 30, 2014 also included approximately \$2 million from the sale of two investments and approximately \$8 million for the negative impact of sequestration in the first quarter of 2014.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Our primary exposure to market risk is to changes in interest rates on our variable rate long-term debt. Our primary variable rate debt relates to our revolving credit facility and term loan commitment under our credit agreement. See Note 4, Long-term Debt, and Note 6, Fair Value Measurements, to the condensed consolidated financial statements included in Part I, Item 1, Financial Statements (Unaudited), of this report, for additional information regarding our long-term debt.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this report, an evaluation was carried out by our management, including our chief executive officer and chief financial officer, of the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended. Based on our evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report.

Changes in Internal Control Over Financial Reporting

There have been no changes in our Internal Control over Financial Reporting during the quarter ended September 30, 2014 that have a material effect on our Internal Control over Financial Reporting.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

Information relating to certain legal proceedings in which we are involved is included in Note 11, Contingencies and Other Commitments, to the condensed consolidated financial statements contained in Part I, Item 1, Financial Statements (Unaudited), of this report and is incorporated herein by reference and should be read in conjunction with the related disclosure previously reported in our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2014 and June 30, 2014 and our Annual Report on Form 10-K for the year ended December 31, 2013 (the “2013 Form 10-K”).

Item 1A. Risk Factors

There have been no material changes from the risk factors disclosed in Part I, Item 1A, Risk Factors, of the 2013 Form 10-K. Certain information in those risk factors has been updated by the discussion in the “Executive Overview—Key Challenges” section of Part I, Item 2, Management’s Discussion and Analysis of Financial Condition and Results of Operations, of this report, which section is incorporated by reference herein.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Purchases of Equity Securities

The following table summarizes our repurchases of equity securities during the three months ended September 30, 2014:

| Period | Total Number of Shares (or Units) Purchased | Average Price Paid per Share (or Unit) (\$) | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs | Maximum Number (or Approximate Dollar Value) of Shares That May Yet Be Purchased Under the Plans or Programs ⁽¹⁾ |
|--|---|---|--|---|
| July 1 through July 31, 2014 | 1,199 | ⁽²⁾ \$36.12 | — | \$206,944,707 |
| August 1 through August 31, 2014 | — | — | — | 206,944,707 |
| September 1 through September 30, 2014 | — | — | — | 206,944,707 |
| Total | 1,199 | 36.12 | — | |

On October 28, 2013, we announced our board of directors authorized the repurchase of up to \$200 million of our common stock. On February 14, 2014, our board of directors approved an increase in this common stock repurchase authorization from \$200 million to \$250 million. The repurchase authorization does not require the repurchase of a specific number of shares, has an indefinite term, and is subject to termination at any time by our board of directors. Subject to certain terms and conditions, including a maximum price per share and compliance with federal and state securities and other laws, the repurchases may be made from time to time in open market transactions, privately negotiated transactions, or other transactions, including trades under a plan established in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

These shares were purchased pursuant to previous elections by one or more members of our board of directors to participate in our Directors’ Deferred Stock Investment Plan. This plan is a nonqualified deferral plan allowing non-employee directors to make advance elections to defer a fixed percentage of their director fees. The plan administrator acquires the shares in the open market which are then held in a rabbi trust. The plan provides that dividends paid on the shares held for the accounts of the directors will be reinvested in shares of our common stock which will also be held in the trust. The directors’ rights to all shares in the trust are nonforfeitable, but the shares are only released to the directors after departure from our board.

Dividends

On October 15, 2013, we paid the first cash dividend, \$0.18 per share, on our common stock, and we paid the same per share dividend quarterly through July 15, 2014. On July 17, 2014, our board of directors approved an increase in our quarterly dividend and declared a cash dividend of \$0.21 per share that was paid on October 15, 2014 to

stockholders of record on October 1, 2014. On October 21, 2014, our board of directors declared a cash dividend of \$0.21 per share, payable on

January 15, 2015 to stockholders of record on January 2, 2015. We expect quarterly dividends to continue to be paid in January, April, July, and October. However, the actual declaration of any future cash dividends, and the setting of record and payment dates as well as the per share amounts, will be at the discretion of our board each quarter after consideration of various factors, including our capital position and alternative uses of funds.

The terms of our credit agreement allow us to declare and pay cash dividends on our common stock so long as: (1) we are not in default under our credit agreement and (2) our senior secured leverage ratio remains less than or equal to 1.75x. The terms of our senior note indenture allow us to declare and pay cash dividends on our common stock so long as (1) we are not in default, (2) the consolidated coverage ratio (as defined in the indenture) exceeds 2x or we are otherwise allowed under the indenture to incur debt, and (3) we have capacity under the indenture's restricted payments covenant to declare and pay dividends. We believe we currently have adequate capacity under these covenants to pursue the dividend strategy described in this report for the foreseeable future based on the capacity as of September 30, 2014 and anticipated restricted payments. See Note 4, Long-term Debt, to the condensed consolidated financial statements included in Part I, Item 1, Financial Statements (Unaudited), of this report and Note 8, Long-term Debt, to the consolidated financial statements accompanying the 2013 Form 10-K.

Our preferred stock generally provides for the payment of cash dividends subject to certain limitations. See Note 10, Convertible Perpetual Preferred Stock, to the consolidated financial statements accompanying the 2013 Form 10-K.

Our credit agreement and our senior note indenture do not limit the payment of dividends on the preferred stock.

Item 6. Exhibits

See the Exhibit Index immediately following the signature page of this report.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.

HEALTHSOUTH CORPORATION

By: /s/ Douglas E. Coltharp
Douglas E. Coltharp
Executive Vice President and Chief Financial Officer

Date: October 28, 2014

EXHIBIT INDEX

The exhibits required by Regulation S-K are set forth in the following list and are filed by attachment to this report unless otherwise noted.

| No. | Description |
|------|---|
| 3.1 | Restated Certificate of Incorporation of HealthSouth Corporation, as filed in the Office of the Secretary of State of the State of Delaware on May 21, 1998 (incorporated by reference to HealthSouth's Annual Report on Form 10-K filed with the SEC on June 27, 2005). |
| 3.2 | Certificate of Amendment to the Restated Certificate of Incorporation of HealthSouth Corporation, as filed in the Office of the Secretary of State of the State of Delaware on October 25, 2006 (incorporated by reference to Exhibit 3.1 to HealthSouth's Current Report on Form 8-K filed on October 31, 2006). |
| 3.3 | Amended and Restated Bylaws of HealthSouth Corporation, effective as of October 30, 2009 (incorporated by reference to Exhibit 3.3 to HealthSouth's Quarterly Report on Form 10-Q filed on November 4, 2009). |
| 3.4 | Certificate of Designations of 6.50% Series A Convertible Perpetual Preferred Stock, as filed with the Secretary of State of the State of Delaware on March 7, 2006 (incorporated by reference to Exhibit 3.1 to HealthSouth's Current Report on Form 8-K filed on March 9, 2006). |
| 10.1 | Second Amendment and Additional Tranche Term Loan Amendment to Third Amended and Restated Credit Agreement, dated as of September 22, 2014, among HealthSouth Corporation, Barclays Bank PLC, as administrative agent and collateral agent, Citigroup Global Markets Inc., as syndication agent, Bank of America, N.A., Goldman Sachs Lending Partners LLC, and Morgan Stanley Senior Funding, Inc., as co-documentation agents, and various other lenders from time to time (incorporated by reference to Exhibit 10.1 to HealthSouth's Current Report on Form 8-K filed on September 24, 2014). |
| 25.1 | Form T-1 Statement of Eligibility under the Trust Indenture Act of 1939, as amended, of Wells Fargo Bank, National Association, as successor trustee under the indenture for debt securities. |
| 31.1 | Certification of Chief Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
| 31.2 | Certification of Chief Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
| 32.1 | Certification of Chief Executive Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
| 32.2 | Certification of Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
| 101 | Sections of the HealthSouth Corporation Quarterly Report on Form 10-Q for the quarter ended September 30, 2014, formatted in XBRL (eXtensible Business Reporting Language), submitted in the following files: 101.INS XBRL Instance Document |

Edgar Filing: HEALTHSOUTH CORP - Form 10-Q

| | |
|---------|--|
| 101.SCH | XBRL Taxonomy Extension Schema Document |
| 101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document |
| 101.DEF | XBRL Taxonomy Extension Definition Linkbase Document |
| 101.LAB | XBRL Taxonomy Extension Label Linkbase Document |
| 101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document |